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ABSTRACT 
Background: While mental health concerns are known to occur commonly for those with 
inflammatory bowel disease (IBD), the nature of this comorbid relationship has not been 
systematically reviewed to date. A review in 2007 identified five controversies regarding 
anxiety/depression rates and various comparators between and within IBD (1). We aimed to 
systematically analyse and critique the current evidence regarding this comorbidity, providing an 
update to the five controversies. 
Methods: Ebscohost Medline, CINAHL, Embase, and PsychINFO were searched between 2005 
and 2014 using systematic review methodology. Controlled quantitative studies examining either 
symptoms or diagnoses of anxiety and depression in IBD were included in the review, with study 
quality assessed using a scale developed a priori to evaluate observational research.   
Results: (1) IBD versus healthy controls (pooled mean proportions) (n=13 studies): Anxiety 19.1% 
vs 9.6%, depression 21.2% vs 13.4%; (2) IBD inactive versus IBD active disease (n=26): Anxiety 
28.2 YV  GHSUHVVLRQ  YV   XOFHUDWLYH FROLWLV 8& YHUVXV &URKQ¶V GLsease 
(CD) (n=28): Anxiety 31% vs 37%, depression 22% vs 24.4%; (4) IBD versus other chronic 
medical conditions (n=17): Anxiety 41.9% vs 48.2%, depression 14.5% vs 28.4%; (5) Onset of 
anxiety/depression before or after IBD onset (n=2): adults more likely to develop 
anxiety/depression prior to IBD onset, but substantial proportion develop depression after onset; an 
increased risk for children of developing anxiety/depression following IBD onset. 
Conclusions: The high rates of anxiety and depression for those with IBD, particularly when 
disease is active, warrant a systemic approach to screening and treatment.  
Keywords: anxiety; depression; inflammatory bowel disease; systematic review 
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INTRODUCTION 
Inflammatory bowel diseases (IBD), RIZKLFK&URKQ¶VGLVHDVe (CD) and ulcerative colitis (UC) are 
subtypes, are chronic relapsing inflammatory conditions of the gastrointestinal tract with unclear 
aetiology and unpredictable course. Currently, 322 per 100,000 people are diagnosed with CD and 
up to 505 per 100,000 people are affected by ulcerative colitis around the world (2).  
Due to the multiple challenges of this disease, including its incurability, unpredictability, 
VHYHULW\RIV\PSWRPVDVZHOODVVXUJHU\DQGPHGLFDWLRQVLGHHIIHFWVSDWLHQWV¶TXDOLWy of life (QoL) 
can be profoundly impaired, resulting in a significant psychosocial burden (3-8). In particular, a 
sizeable proportion of individuals with IBD have been identified as experiencing co-morbid anxiety 
and/or depression (8, 9). When left untreated, these mental disorders have been linked to more 
severe IBD symptoms and more frequent IBD flares (7), higher hospitalisation rates (10), and lower 
compliance with treatment (11) than for individuals without these co-morbidities. However, despite 
their frequency, psychological symptoms in IBD remain largely untreated. A recent Dutch study 
(n=231) showed that over 60% of adult IBD patients attending a tertiary care centre with co-morbid 
anxiety and/or depressive symptoms did not receive adequate care (12). According to a recent 
national audit in the United Kingdom (UK), only 12% of IBD services have access to clinical 
psychology via a defined referral pathway (13).  
A significant contributor to the lack of recognition for the importance of mental health in 
IBD is the quality of available evidence. Psychological and psychiatric research in IBD has 
traditionally been plagued by an abundance of small and often poorly controlled studies with 
diverse methodologies and settings, which present conflicting findings and consequently make it 
difficult to draw any firm conclusions from the data. No systematic reviews documenting and 
clarifying this comorbidity have been published to date and thus no high-level evidence has 
informed the guidelines on IBD management in relation to the mental health of patients with IBD. 
In 2007, the first author and her collaborators published a review paper exploring the comorbidity 
of anxiety and depression with IBD (1). We endeavoured to answer five major questions related to 
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rates of depression and anxiety, comparing groups both within IBD (i.e. active and inactive disease; 
CD and UC; onset before or after IBD onset), and between IBD and other groups (i.e., healthy 
individuals; individuals with other chronic medical conditions). However, since the quality of the 
available 17 studies at the time was poor, it was difficult to provide an answer to these questions, 
other than to confirm that anxiety and depression were highly prevalent within IBD. The academic 
community was invited to address these controversies by designing high quality studies. Indeed, in 
recent years, studies of anxiety and depression in IBD have proliferated all over the world, with 
some excellent large-scale population-based research, for example, providing a rich source of data 
for better understanding of psychiatric and psychological co-morbidity in the IBD context. 
In the present review we systematically identify, analyse and critique the current evidence in 
relation to the comorbidity of anxiety, depression and IBD, revisiting and providing an updated 
response to the following questions: 
Controversy 1: Are rates of anxiety/depression (both symptoms and disorders) in IBD similar 
or different to that reported for the healthy/general population controls? 
Controversy 2: Are rates of anxiety/depression (both symptoms and disorders) similar or 
different during active versus inactive IBD? 
Controversy 3: Are rates of anxiety/depression (both symptoms and disorders) similar or 
different in UC versus CD? 
Controversy 4: Are rates of anxiety/depression (both symptoms and disorders) in IBD similar 
or different to that reported in other groups of medically ill patients?  
Controversy 5: Do anxiety/depression (both symptoms and disorders) precede and/or follow 
onset of IBD? 
In the previous review, databases were searched for papers published between 1980 and 2005; 
we are now re-assessing the status of these controversies and reporting progress in the 
understanding of these relationships by reviewing all available studies published from 2005 until 
2014. 
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MATERIALS AND METHODS 
This systematic review was registered in the International Prospective Register of systematic 
reviews PROSPERO (CRD42014014960).  
 
Types of studies 
Studies meeting the selection criteria listed below were included. 
Inclusion criteria 
x Studies concerning IBD LQFOXGLQJ &URKQ¶V GLVHDVH XOFHUDWLYH FROLWLV DQG LQGHWHUPLQDWH
colitis) diagnosed using any well-established criteria (e.g. Montreal classification); 
x Studies examining either symptoms (based on validated screening scales e.g. the Hospital 
Anxiety and Depression Scale (HADS)) or diagnosis (based on a clinical interview such as 
the Structured Clinical Interview for DSM (SCID)) of anxiety and depression; 
x Studies with either adult or paediatric populations; 
x Studies published between 2005 and 2014; 
x Controlled studies, including randomised controlled trials (baseline data only), with any of 
prospective, retrospective and cross-sectional designs; 
x Peer-reviewed papers. 
Exclusion criteria 
x Studies using mood or quality of life scales where no independent anxiety or depression 
scale/dimension exists; 
x Studies focusing on other psychological variables such as distress, coping, personality or 
quality of life, without specific measures of depression or anxiety; 
x Interventional studies (i.e. natural course of IBD / mental disorders cannot be observed);  
x Studies in languages other than English; 
x Studies published before 2005 as the study is an update to a previous review (1); 
x Conference abstracts or any short papers with incomplete data presented; 
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x Case reports, case series or qualitative research; 
x Reviews, opinion papers; 
x Animal studies. 
 
Search methodology 
Sources  
A systematic and comprehensive literature search of Ebscohost Medline, CINAHL, Embase, and 
PsychINFO was conducted in November and December 2014.  
 
Search strategy 
Two versions of a search strategy, using relevant search terms, were used: 1) FULL: Limited to peer 
reviewed AND NOT case-studies OR dissertations OR animal studies; 2) LIMITED: Limited to 
peer reviewed AND NOT case-studies OR dissertations OR animal studies AND only published 
between 2005 and 2014. Table 1 provides the search strategy and search results. Reference 
management was done through EndNote (version X6 Thomson Reuters).  
 
Data collection and analysis 
The systematic review was undertaken based upon the recommended PRISMA statement guidelines 
(http://www.prisma-statement.org) (Appendix 1). In the first phase, two reviewers independently 
screened the titles and abstracts identified by the search to determine whether they met the inclusion 
criteria. Any disagreements were resolved by discussion with a third reviewer. In the second phase, 
the full papers of those identified in phase one were independently evaluated by two reviewers to 
determine if they included data to address any one or more of the five controversies.  That is, after 
checking general selection criteria, papers were screened again to verify whether information 
required to respond to a particular controversy was reported (e.g. in controversy 2, we checked 
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whether data for depression/anxiety by active and inactive IBD were reported), with disagreements 
resolved through discussion with a third reviewer (see Figure 1 for exclusion reasons).    
Given the general heterogeneity of studies - the range of different recruitment strategies, 
settings, participant groups, outcome measures, methodologies - there was a limited scope for a 
meta-analysis. Further, this review focused on anxiety and depression rates at one point in time 
(controversies 1-4) or before/after IBD onset (controversy 5) rather than on treatment effect. We 
calculated mean percentages (and 95% confidence intervals (CI) or odds ratios, as appropriate) for 
rates, and weighted means on a common scale where data were available.  
 
Data extraction 
Extracted data included: authors, year of publication, and country of origin, design, setting, 
participant characteristics (IBD subtype, age, gender, disease activity status) and sample size, 
outcome measures, and results for main outcome measures. 
 
Data synthesis 
We provided a narrative synthesis of the findings from the included studies, structured around the 
co-occurrence of anxiety and depression with IBD, calculating mean percentages for the IBD and 
appropriate comparator group. 
 
Quality and risk of bias assessment 
Two reviewers independently inspected the full articles identified for inclusion for each 
controversy, to evaluate study quality. Any disagreement was discussed with a third reviewer. The 
quality appraisal of the studies was assessed using a scale developed a priori for the specific needs 
of this study (see Appendix 2), based on recommendations from Sanderson (14) regarding key 
domains to assess in critical appraisal. The scale included evaluation of 1) appropriate selection of 
participants; 2) appropriate measurement of variables; and 3) appropriate control of confounding 
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variables. We also consulted with IBD experts not involved in this review regarding the scale, and 
piloted it with a sub-sample of studies before undergoing the quality appraisal of the included 
articles. We interpreted the quality in the following manner: if the mean quality score for the 
controversy was between 0-30% on the rating scale it was considered low; if it was between 31-
60% it was considered moderate; and if it was between 61-100% it was considered high. 
 
RESULTS 
Of the 4,985 studies identified during the database searches, 1,264 were removed as duplicates. Of 
the 3,721 papers for which we screened titles and abstracts, 3,511 did not meet the inclusion criteria 
(see Figure 1), leaving 210 included for full review to determine specific applicability for each 
controversy. In controversy 1, 13 studies were included in the final review; 26 studies were 
applicable for controversy 2; 28 studies for controversy 3; 17 studies for controversy 4; and 2 
studies for controversy 5. This amounts to 66 unique studies, as some studies addressed more than 
one controversy. 
 
Study characteristics 
Study characteristics are presented in Tables 2-6. 
Controversy 1: IBD versus healthy/general population controls 
Of the 13 studies which had applicable data in relation to this question (9, 15-26), seven came from 
Europe, five from North America, and one from Australia. Seven were cross-sectional, three were 
case-control, and three were cohort studies, two of which were prospective and one was 
retrospective. Samples ranged in size from 47 to 2,144 IBD participants (total n=4,098) and from 20 
to 10,720 healthy or general population controls (total n=13,190). Five studies included paediatric 
/adolescent populations. In terms of anxiety and depression measurement, the majority incorporated 
self-report measures, with the HADS being the most common measure (n=6) (15-17, 20, 24, 26). 
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Two studies used diagnostic information (International Statistical Classification of Diseases-9 
(ICD-9) codes, n=1; Comprehensive International Diagnostic Interview (CIDI); n=1) (9, 22). 
 
Controversy 2: IBD active versus IBD inactive 
Overall, 26 studies had applicable data in relation to this controversy (4, 18, 20, 27-49). Of these, 13 
came from Europe, 12 from North America, and one from Korea. Fifteen were cross-sectional, 
seven were prospective cohorts, including one that was population-based, two were retrospective 
cohorts, there was one case-control study, and one was a randomised controlled trial where just the 
baseline data was used. Samples ranged in size from 47 to 10,634 (total n=15,931) participants. Of 
the 26 studies, three (total n=11,062) did not report total numbers of participants or provide 
percentages of those with active versus inactive IBD. Of the remaining 23 studies (n=4,805), 2,297 
(48%) participants were in an inactive disease phase; not included in this proportion were six 
studies which presented data for participants with inactive IBD only (n=784). Anxiety and 
depression were most frequently measured using the HADS (n=11) (20, 29, 31-33, 36, 39, 41, 46, 
49, 50). For disease activity measurement, in CD, the most commonly used was the Crohn¶s 
Disease Activity Index (CDAI) (n=12) (20, 27, 28, 30, 31, 36, 38, 43, 46-49) while in UC, it was 
the Simple Clinical Colitis Activity Index (n=4) (20, 35, 38, 43).  
 
Controversy 3: CD versus UC 
Overall, 28 studies met the inclusion criteria in relation to this question (20, 21, 26, 27, 29, 33, 38, 
39, 41, 43, 46, 47, 51-66). Of these, 17 came from Europe, 8 came from North America, two from 
Australia, and one from Korea. Twenty-two were cross-sectional, three were prospective-based 
studies, two were cohort studies and one was a population-based case control study. Samples ranged 
in size from 48 to 11,028 IBD participants (total n=42,564), with subsets of CD participants ranging 
from 26 to 6,689 (n=23,564), and UC participants ranging from 22 to 5,522 (n=19,319). Two 
studies included paediatric/adolescent populations. The HADS was the most commonly used 
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anxiety or depression scale (n=16) (20, 26, 29, 33, 39, 41, 46, 54, 56-59, 61-64). Two studies used 
the ICD-9 criteria (51, 52). In terms of disease activity, for CD, the CDAI was used most commonly 
(n=10) (27, 38, 43, 46, 47, 55, 60, 62-64) while for UC, the SCCAI was most commonly used (n=5) 
(20, 26, 38, 43, 53).  
 
Controversy 4: IBD versus medically ill controls 
Overall, 17 studies met the inclusion criteria in relation to this controversy (15, 17, 21, 24, 27, 67-
78). Of these, 12 came from Europe, two from Australia, one from Brazil, Malaysia, and the USA. 
Fifteen studies were cross-sectional, with one of these reporting gender- and age-matching, one was 
a cohort-based study and one was a population-based case study. Three of the 17 studies were based 
on child/adolescent cohorts. Samples ranged in size from 26 to 305 IBD participants (total 
n=1,874), and from 38-1506 for the medically ill controls (total n=3419). The most common 
comparator was irritable bowel syndrome, used in six studies, with four studies using a mix of 
illness groups (e.g. chronic liver disease, celiac, food allergy), two studies utilising colon cancer 
groups as comparators, and the remaining five studies using participants with gastroesophageal 
reflux disease (GERD), juvenile idiopathic arthritis, multiple sclerosis (MS), rheumatoid arthritis 
(RA) or self-limited colitis cohorts (ASLC), respectively as comparators. The most commonly used 
measure of anxiety or depression was the HADS (n=8) (15, 17, 24, 67-69, 74, 75).  
 
Controversy 5: Preceding or following IBD onset 
Only two studies (n=2,495) had applicable data in relation to this controversy (9, 22). Both were 
cohort studies from North America, with one of them being population-based. One examined a 
paediatric IBD population (n=2,144) and the other studied an adult IBD population (n=351), with 
10,720 paediatric and 779 adult age- and gender-matched controls, respectively. Diagnostic criteria 
for anxiety and depression were used in both studies (ICD9 codes; CIDI). IBD was identified using 
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the ICD9 coding in the paediatric study, and using a validated administrative data definition which 
was then verified through a chart review in the adult study. 
 
Anxiety and Depression Study Outcomes 
Controversy 1: IBD versus healthy/general population controls 
Eleven of the 13 studies measured anxiety, with seven of these reporting either significantly higher 
rates (% or levels (mean scores) of anxiety in those with IBD than in healthy control participants 
(n=3,262 IBD; n=12,024 controls) (9, 15, 20-22, 24, 26).  
For adult IBD participants, the rates of anxiety ranged from 15.1% (± 3.75, 95% CI) [all 
anxiety combined] based on diagnostic criteria in the population-based study by Walker (9), to 40% 
(±14.1, 95% CI), reported in a small case control study measuring anxiety symptoms for those with 
CD only (18). The rates for healthy controls were 16.3% (± 2.6, 95% CI) and 7.6% (± 6.4, 95% CI) 
in these studies, respectively. In children, a small cross-sectional study found low rates of clinically 
significant anxiety for both the IBD participants (2% ± 3.88, 95% CI) and the healthy non-IBD 
individuals (5% ± 6.59, 95% CI) (23). A pooled mean rate of anxiety symptoms in all IBD samples 
reporting proportions (study n=3 (9, 18, 23); total IBD n=448) was 19.1% (± 3.63, 95% CI) 
compared to 9.6% (± 1.94, 95% CI) in healthy controls (n=887).  
All 13 studies examined depression. Nine found significantly higher rates and/or levels of 
depression in IBD participants than in healthy controls (n=3,517 IBD; n=12,212 controls) (9, 15, 
16, 19-22, 24, 26). Two studies with adolescents (one cross-sectional and one prospective; total 
n=734) (23, 25), reported the opposite relationship, namely that healthy non-IBD individuals had 
higher rates/levels of depression than those with IBD, although only one of these studies found that 
the group differences were significant (n=78 IBD; n=564 controls) (25).  
Depression rates for adults with IBD ranged from 7% (± 7.3, 95% CI) reported in a small 
case control study (18), to 59% (± 6.2, 95% CI) in a population-based case control study with nearly 
500 participants (21). The latter study however used the BDI, which can overestimate depression in 
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medically ill populations including IBD, due to its emphasis on somatic symptoms. A population-
based IBD study which used the gold standard of a structured clinical diagnostic interview reported 
that 27.2% (± 4.7, 95% CI) of cases met criteria for lifetime depression illness (9). Rates of 
depression for the healthy control individuals were 1.5% (± 2.9, 95% CI), 38% (± 5.9, 95% CI), and 
12.3% (± 2.3, 95% CI) in these studies, respectively. In children, the rates of depression ranged 
from 0% (versus 2% [± 4.2, 95% CI] in controls) in a small cross-sectional study (23) to 13% (± 
7.5, 95% CI) in another cross-sectional study (rates unreported for controls) (25). A pooled mean 
rate of depressive symptoms in all IBD samples reporting percentages (study n=5; total n=767) was 
21.2% (± 2.9, 95% CI) compared to 13.4% (± 1.9, 95% CI) for healthy controls (n=1,142). 
 
Controversy 2: IBD active versus IBD inactive 
Of the 26 studies, 21 measured anxiety, with six of these providing data for inactive IBD only (28, 
32, 36, 37, 39, 49). Of the remaining 15, 11 reported significantly higher rates or levels of anxiety in 
participants with active IBD compared to those with inactive IBD (n=13,585) (4, 18, 20, 27, 29, 31, 
38, 41, 42, 44, 45). A study by Goodhand et al. (20), which reported disease activity results 
stratified by IBD disease type, found that those with active UC or active CD had higher rates of 
anxiety than those with inactive disease, although the findings were only significant for the UC 
group. Only one cross-sectional study reported slightly lower levels of anxiety in individuals with 
active IBD compared to participants with inactive IBD, although the group differences were not 
statistically significant (n=147) (46). 
In adults, the rates of anxiety in inactive IBD ranged from 9.1% (± 9.8, 95% CI) in a small 
case-control study (18) to 70.6% (± 11.8, 95% CI) in another small study (32). The pooled mean 
rate for all the studies reporting percentages (study n=8; total n=1,069) was 28.2% (± 2.7, 95% CI) 
(18, 27-29, 32, 33, 36, 39). In the four largest studies (n=839) which provided data on rates, 22% (± 
2.8, 95% CI) of IBD patients with inactive IBD had clinically elevated anxiety (28, 29, 33, 39). 
During active disease, the rates of anxiety were typically much higher, ranging from 56.3% (± 17.2, 
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95% CI) to 71.4% (± 9.1, 95% CI), with a pooled mean rate of 66.4% (± 7.8, 95% CI) (study n=3; 
total n=140) (18, 27, 29). In the largest sample reporting rates for active IBD, 71.4% (± 9.1, 95% 
CI) of IBD patients with active IBD had elevated anxiety (27). No data for children were available. 
Of the 26 studies, 23 measured depression, with six providing data for inactive IBD only. Of 
the remaining 17 studies, 12 reported significantly higher rates or levels of depression for those with 
active IBD (n=13,553) (18, 20, 27, 29, 31, 34, 35, 38, 41, 43, 45, 48). In adults, the rates of 
depression in inactive IBD ranged from 0 in one small study (n=33) (18) to 49.6% (±14.3, 95% CI) 
in another small study (n=47) (40). The pooled mean rate of depressive symptoms for those with 
inactive IBD was 19.9% (± 2.05, 95% CI) (study n=10; total n=1,132) (18, 27-29, 32, 33, 36, 39, 
40, 48). During active disease, the rates of depression ranged from 14% (± 18.2, 95% CI) in a small 
case-control study (18) to 50% (± 18.5, 95% CI) in a small prospective study (n=28) (40). The 
pooled mean rate of depressive symptoms during active IBD was 34.7% (study n=5; total n=319) 
(18, 27, 29, 40, 48). For children, one study (n=156) reported a 30% rate of depression (± 7.2, 95% 
CI) in inactive IBD (48), and a depression rate of 49% (±7.97, 95% CI; n=151) for those with active 
disease (48).  
 
Controversy 3: CD versus UC 
Twenty-one of the 28 studies measured anxiety, with only three of them concluding there were 
statistically significant differences between IBD subtypes, all of which indicated higher anxiety for 
those with CD (21, 29, 41). Based on 14 studies reporting anxiety rates, the pooled average was 
37% (+ 9.9, 95% CI) for CD (n=1144) and 31% (+ 14.2, 95% CI) for UC (n=628). Nine of 24 
studies reported mean HADS scores; the mean HADS-A score for CD (n=1818) was 7.0 (+ .85, 
95% CI) and the mean HADS-A score for UC (n=1423) was 6.4 (+ .5, 95% CI). No data for 
children were available. 
Twenty-seven of 28 studies assessed depression, however, only two studies noted significant 
differences, demonstrating higher depression rates in CD (39, 41). The pooled average depression 
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rate, acquired from 15 of the 27 studies, was 24.4% (+ 7.3, 95% CI) for CD (n=9496) and 22% (+ 
6.9, 95% CI) for UC (n=7136). Pooled means for HADS-D scores (n=8/27 studies) were 6.09 (+ 
.89, 95% CI) for CD (n=1299) and 5.5 (+ 1.08, 95% CI) for UC (N = 1694). Two studies with 
adolescent (55, 60) and one with elderly populations (43) were available, all three showing no 
difference between CD and UC participants in rates or levels of depression. 
 
Controversy 4: IBD versus medically ill controls 
Fourteen of the 17 studies assessed anxiety. Of these only six studies (n=915 IBD and 815 controls) 
showed the differences between IBD and other medically ill participants to be statistically 
significant (17, 21, 71, 74, 77, 78). Three studies (n=276 IBD and 213 controls) (21, 77, 78) 
reported significantly lower rates of anxiety in IBD than in controls with IBS or self-limited colitis, 
while another three studies (n=639 IBD and 602 controls) showed IBD participants as having 
higher rates of anxiety than controls with rheumatoid arthritis, colorectal cancer and several other 
disorders (coeliac disease, food allergy, congenital disorders) (17, 71, 74). The pooled average 
anxiety rate was 41.9% (+ 9.2, 95% CI) for IBD and 48.2% (+ 31.1, 95% CI) for controls. HADS-A 
scores (n=6 studies), for IBD had a mean of 7 (+ 1.2, 95% CI) versus 8.4 (+ 1.4, 95% CI) among 
controls. One study showed that adolescents with IBD had significantly higher rates of anxiety than 
controls with congenital disorders, food allergy, coeliac disease but not those with chronic liver 
disease (17). 
Of the 17 studies assessing depression, 10 showed statistically significant differences 
between IBD and other medically ill cohorts (17, 21, 67, 68, 70, 71, 73-75, 77). Five (n=551 IBD 
and 372 controls) (67, 73-75, 77) reported lower rates or levels of depression in IBD than in 
controls with IBS, hepatitis C, rheumatoid arthritis, and multiple sclerosis, and five (n=648 IBD and 
601 controls) (17, 21, 68, 70, 71) indicated higher rates or levels in IBD than in participants with 
self-limited colitis, colorectal cancer, juvenile idiopathic arthritis, and several other conditions 
(coeliac disease, food allergy, GERD, congenital disorders). A pooled mean depression rate was 
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14.5% (+ 10.5, 95% CI) in IBD (n=550) versus 28.4% (+ 17.7, 95% CI) in controls (n=1567). 
When data from the studies reporting HADS scores (5 of 17 studies) were pooled, IBD participants 
(n=686) had mean HADS-D scores of 3.9 (+ .6, 95% CI) compared to 4.6 (+ .6, 95% CI) in controls 
(n=694). Three studies provided data for paediatric populations (17, 70, 72) but only two conducted 
significance testing, both showing higher rates of depression in IBD than controls with juvenile 
idiopathic arthritis, congenital disorders, food allergy, coeliac disease but not chronic liver disease 
(n=339 IBD and 382 controls) (17, 70). 
 
Controversy 5: Preceding or following IBD onset 
No prospective studies examining rates of anxiety and depression prior to IBD diagnosis were 
identified from the past decade. However, two studies were relevant to this controversy, examining 
incidence of anxiety and depression post-diagnosis in children, and retrospective evaluation of 
timing of onset in relation to IBD in adults (9, 22).  
For adults, 70% of those with IBD and a lifetime history of an anxiety or mood disorder, had 
a first episode of an anxiety disorder 10 years or more before the IBD diagnosis, while just 8% 
developed anxiety two or more years after IBD onset, suggesting anxiety is much more likely to 
predate the IBD. Overall, the lifetime prevalence of anxiety was 15.1% (± 3.7, 95% CI) versus 
16.3% (± 2.6, 95% CI) for age and gender-matched controls (9). In children with IBD, the incidence 
rates of anxiety disorders (1.81 per 100 patient-years of observation) were significantly higher than 
in the healthy controls (0.57 cases, p< 0.0001). After adjustment for IBD patient characteristics, 
having CD was associated with more than a twofold increase in the risk of developing anxiety 
disorders in the paediatric population (HR = 2.28; 95% CI = 1.65±3.17; p < 0.0001 for both 
comparisons) (n=2,144 CD patients and n=10,720 controls)  (22).  
With regard to depression in adults, 54% of those with IBD and a lifetime history of an 
anxiety or mood disorder had an onset of depression two years or more before the IBD onset while 
23% developed depression two or more years after IBD onset, suggesting risk both before and after 
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disease onset. The lifetime prevalence of depression was 27.2% (± 4.7, 95% CI) versus 12.3% (± 
2.3, 95% CI) for age and gender matched controls (13). In children with IBD, the incidence rate of 
depressive disorders (2.69 cases per 100 patient-years of observation) was significantly higher than 
in the healthy controls (1.22 cases, p< 0.0001). After adjustment for patient characteristics, having 
CD was associated with a 74% increase in the risk of developing depression (HR = 1.74; 95% CI = 
1.35± 2.25, p < 0.0001) (n=2,144 CD patients and n=10,720 controls) (22).  
In adults, mean age of IBD onset with lifetime anxiety or mood disorder was 29.1 years as 
compared to 33.1 years in those with IBD and without an anxiety or mood disorder (p=0.012) (9). 
No such data were available for children. 
 
Quality appraisal 
Quality scores for each study are presented in Tables 2-6. 
Controversy 1: IBD versus healthy/general population controls 
Quality ranged from 5 to 12 of a maximum 14 points, with a mean of 7.5 (53.6%), indicating a 
moderate quality. Overall, seven studies scored at least 50% on the quality scale.  
 
Controversy 2: IBD active versus IBD inactive 
Quality ranged from 3 to 11 of a maximum 15 points, with a mean of 7.3 (48.6%), indicating a 
moderate quality. Overall, 12 studies scored over 50% (a score of at least 8) on the quality scale. 
 
Controversy 3: CD versus UC 
Quality ranged from 3 to 11 of a maximum 12 points, with a mean of 5.7 (47.5%), indicating a 
moderate quality. Overall, 12 studies scored at least 50% on the quality scale.  
 
Controversy 4: IBD versus medically ill controls 
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Quality ranged from 4 to 11 of a maximum 14 points, with a mean of 6.4 (45.7%), indicating a 
moderate quality. Overall, nine studies scored at least 50% on the quality scale.  
 
Controversy 5: Preceding or following IBD onset 
Quality ranged from 11 to 12 of a maximum 14 points in the two included studies, and was 
considered high, with a mean of 11.5 (82%). 
 
DISCUSSION 
This systematic review examined five primary questions regarding the comorbidity of anxiety and 
depression with IBD. The original review (1), of which the present paper is an update, identified 
these five areas of controversy, but was unable to provide definitive answers to these questions due 
to the paucity of data available at that time. The current review was able to address four of the five 
questions more definitively, as summarized in Table 7. Specifically, in this review we observed that 
there were higher rates of both anxiety and depression symptoms in those with IBD compared to 
healthy individuals without IBD (controversy 1). The bulk of the studies support that the rates of 
both anxiety and depression are higher during active compared to inactive disease phase 
(controversy 2), and that overall rates and mean levels of anxiety and depression are significantly 
but only modestly higher for those with CD compared to UC (controversy 3). Rates of anxiety and 
depression in IBD were observed to be lower when compared to those with other chronic health 
conditions, noting that most of the available comparators were gastrointestinal GI conditions of 
varying clinical severity (controversy 4). Given the variety of comparators and major differences 
between them and IBD in their presentation, aetiology and burden, the biopsychosocial mechanisms 
behind this finding prove difficult to decipher.  
Almost all of the studies measured symptoms of anxiety or depression, and not clinically 
diagnosed disorders, so the mean rates presented may be higher than rates of anxiety and mood 
disorders. While there is some relationship between elevated symptom scores and clinical diagnoses 
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of mood and anxiety disorders, they are not fully concordant (79, 80). Nevertheless, the Walker 
study (9), which was population-based, had age and gender-matched controls, and used a structured 
diagnostic interview, the gold-standard for clinical diagnosis, clearly indicated elevated rates of 
depression for individuals with IBD.  
The quality of evidence for these first four research questions, in terms of study design, was 
moderate, so there can be some confidence in the observations. However, further method 
improvements are needed. Study participants were commonly recruited as convenience samples 
from clinics, increasing the potential for bias and threats to external validity. Only 10% of the 
studies which met the inclusion criteria and had applicable data to address these research questions 
were population-based. The reliance on symptom measures, the wide variability of screening 
measures used, the use of differing cut-offs even with the same measures (e.g., HADS cut-off of >7, 
>8, > 8, >11), and the range of ways that mental health data was reported (e.g., different measures 
of central tendency and variability), make cross comparison difficult, adding confusion and 
unnecessary heterogeneity in this area. As well, the majority of studies did not provide sample size 
calculations, despite the need for such calculations in every scientific study to ensure that there is 
sufficient power so that if a difference of clinical interest is found, it is likely to be statistically 
significant (81).   
The most challenging aspect to address regarding the comorbidity of anxiety and depression 
with IBD is whether these mental disorders precede or develop after IBD onset (controversy 5). The 
vast majority of studies used a cross-sectional design and were unable to shed light on this question, 
with only 2 of the 210 studies which met general inclusion criteria having applicable data (9, 22). 
The study which evaluated adults found that the large majority of individuals had first onset of 
anxiety well before the IBD (more than 10 years) (9). Since anxiety onset is very common in 
adolescence and young adulthood, the high rates of anxiety onset around this time point may well 
be reflecting the natural course of an anxiety disorder. With regard to depression, just over half of 
those experiencing depression had first onset of depression prior to IBD onset, with one-quarter 
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developing the depression a few years or more after IBD onset (9). These findings are intriguing, 
and raise the question of bidirectional risk. They are in line with experimental work with animals, 
which has demonstrated that depression may precede and can increase vulnerability to inflammation 
(82, 83). However, the timelines were established retrospectively through structured clinical 
interviews to determine lifetime prevalence of mental disorders, so there is potential for recall bias. 
The epidemiological study of children, which evaluated incident cases of depression and anxiety, 
concluded that having IBD increased the risk of developing anxiety or depression (22). Its use of 
diagnostic criteria, large sample size, and age and gender-matched controls provide some 
confidence in the conclusions.   
 
Recommendations  
The high rate of anxiety and depression in individuals with IBD and the impact of mental 
comorbidities on the disease-related outcomes warrant a systemic approach to screening and 
treatment. While studies on mental health in primary care do not always support the value of routine 
screening (84), its benefit has been established in populations with chronic conditions or mental 
disorders (85). However, as was evident in our review, there are a myriad of mental health 
screening measures used, and it is notable that few have been validated in an IBD population (38, 
86). Thus, the approach to and effectiveness of screening for mental disorders as part of IBD care 
has yet to be empirically validated. Nonetheless, new approaches to healthcare delivery such as 
stepped care or integrated care may facilitate better detection and management of anxiety and 
depression coexistent with IBD (87-89).  
This review has demonstrated a significant level of psychological co-morbidities in IBD. 
Yet, treatment of anxiety and depression is often not considered as part of standard IBD care (90). 
While financial strain of the public healthcare systems around the world and medical training of 
IBD physicians to treat the somatic symptoms may contribute to lack of integration of mental health 
care with general IBD care, another contributing factor may be the controversy on the efficacy of 
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mental health treatments in IBD. To date, there have been no published trials on the use of 
antidepressants in IBD (91, 92). Psychotherapy has been more carefully examined, with conflicting 
results. A 2011 Cochrane review, which broadly defined psychotherapy and pooled all modalities 
together, concluded that psychotherapy had no effect on distress, disease activity, or quality of life 
in the unselected IBD patients (93). However, recent reviews which used more appropriate 
categorization of psychological interventions, analysing different types of treatments separately, 
demonstrated that one type of psychotherapy, cognitive-behavioural therapy (CBT), improves 
psychological distress, with modest changes in gastrointestinal symptoms (94, 95). These differing 
conclusions largely stem from methodological differences in the approach to the reviews, but also 
from the paucity of well-designed large-scale clinical trials on psychotherapy in IBD. Clinical trials 
need to ensure sufficient power, selection of participants with elevated distress and active disease, 
validated and objective measures of outcome (e.g., changes in depression, measurement of 
inflammatory processes), and appropriate control conditions (96). Until there is clearer direction 
regarding  the IBD-specific treatment of anxiety and depression, use of  evidenced-based therapies 
such as cognitive behavioural therapy for anxiety and depression in general, as specified in the 
National Institute for Health and Care Excellence (NICE) guidelines, appears prudent (97).  
 
Future directions 
The research on mental health comorbidity in IBD is quite extensive, as evidenced by the thousands 
of citations identified in the search for the past decade alone. The strengths of this review include 
the comprehensive and systematic approach to evaluating this extensive body of literature, the 
inclusion of controlled studies, and the focus on a broad range of comparators both within and 
between those with IBD and others. The review also has some limitations. The available studies 
were largely from Western Europe and North America, with few to none from areas such as Eastern 
Europe, South America, Asia and Africa. As there are differing rates of IBD in various regions of 
the world (2), there may also be differing rates of comorbid depression and anxiety than what was 
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identified in the current review. In addition, we were unable to examine gender differences in 
anxiety and depression comorbidity as virtually no studies provided a male/female breakdown of 
their results. Gender differences in the clinical course of IBD such as earlier disease relapse post-
surgery for women have been reported (98), so a careful evaluation of mental health comorbidity 
for men and women may provide direction for contributory mechanisms. Further, primary 
depression is much more common for women than for men (99). Many of the studies in our review 
had a modestly larger proportion of female participants, raising the possibility that rates are 
somewhat elevated due to overrepresentation of females in these samples. Finally, most of the 
studies involved adult IBD participants, with relatively few providing data for paediatric samples, 
and only one study using a geriatric IBD sample (43). Where data was available, we provided 
anxiety and depression rates that were specific to these age groups, but it is difficult to draw 
conclusions about comparative rates of anxiety and depression for children and the elderly in the 
IBD context at this time.   
We have briefly highlighted some of the ongoing methodological problems and study 
heterogeneity in the clinical literature. In order to improve the quality of research in this area, and 
facilitate the use of meta-analytic approaches in the future, researchers are encouraged to consider 
the following design and reporting elements: a) cohort, case-control designs rather than cross-
sectional; b) population-based or at a minimum consecutively recruited participants; c) comparison 
groups, including both healthy and chronically ill controls; d) justification for the sample size and 
attrition; e) control for confounders (e.g., psychiatric history); f) present data separately for IBD 
subtypes, disease activity, and male/female and provide means (SD) and proportions with 
confidence intervals where appropriate; g) measure IBD outcomes such as time to relapse, as well 
as inclusion of objective measures such as faecal calprotectin, or optimally endoscopy; and h) use of 
validated screening measures as well as validated clinical diagnostic measures (e.g., ICD codes, 
structured clinical interviews), with effort to be more homogeneous. With regard to this latter point, 
there was tremendous variability in measurement of anxiety and depression; 16 scales (5 for both 
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anxiety and depression; 6 for depression alone; and 5 for anxiety alone) were used across the 66 
unique studies examined in this systematic review and only two appear to have been validated in 
individuals with IBD (38, 86). We observed that the HADS was the most commonly used measure, 
among the studies with applicable data for the controversies addressed in this review, and that it 
aims to evaluate anxiety and depression symptoms using a common metric. Despite the extensive 
use of the HADS in medical patients generally (based on PubMed, since its development in the 
1980s it has been used in over 3,700 studies) and with IBD patients to date, it has yet to be 
validated in IBD. It also must be noted that more recently the HADS has been shown to 
differentiate poorly between anxiety and depression (100, 101). Given this, further research is 
required to both validate, and develop clear cut-offs and meaning in the IBD context. 
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BAS = Bates Anxiety Scale  
BDI = Beck Depression Inventory 
CAI = Clinical Activity Index 
&' &URKQ¶VGLVHDVH 
&'$, &URKQ¶V'LVHDVH$FWLYLW\,QGH[ 
CDI = &KLOGUHQ¶V'HSUHVVLRQ,QYHQWRU\ 
CIDI = Comprehensive International Diagnostic Interview 
CRP = C-reactive protein 
DAI = Modified/Simplified Disease Activity Index 
ESR = erythrocyte sedimentation rate 
GDS = Geriatric Depression Scale 
HADS = Hospital Anxiety and Depression Scale 
HAM = Hamilton Anxiety and Depression (HAM-A = anxiety scale; HAM-D = depression scale) 
Hb = haemoglobin  
HBI = Harvey Bradshaw Index  
HC = healthy controls 
IBD = inflammatory bowel disease 
IBS = irritable bowel syndrome 
IQR = inter-quartile range 
LCAI = Lichtiger Colitis Activity Index 
MIBDI = Manitoba IBD index  
MSDAI = Mayo Score Disease Activity Index 
N/A = not available 
ns = not significant 
PCDAI = 3DHGLDWULF&URKQ¶V'LVHDVH$FWLYLW\,QGH[ 
PGWBI = Psychological General Wellbeing Index 
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PHQ = Patient Health Questionnaire 
PROMIS = Patient Reported Outcomes Measurement Information System 
RMAS = Revised Manifest Anxiety Scale  
6$, 6HR¶V$FWLYLW\,QGH[ 
SCARED = Screen for Child Anxiety Related Disorders 
SCCAI = Simple Clinical Colitis Activity Index  
SCL90R = Symptom Checklist questionnaire- revised 
SD = standard deviation 
STAI = State-trait Anxiety Inventory 
TWI = Truelove-Witts Index 
UC = ulcerative colitis  
Zung SDS = Zung Self-Rating Depression Scale  
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Table 1: the search strategy and search results 
 
 
Ebscohost Medline CINAHL Embase PsychINFO 
IBD KEY WORDS FULL (N) Limited (N) FULL (N) Limited (N) FULL (N) Limited (N) FULL (N) Limited (N) 
³Inflammatory bowel´ 31,361 19,001 2,626 2,055 47,740 33,491 407 272 
colitis 53,511 20,895 2,669 1,904 97,954 50,637 637 194 
³Crohn disease´ 28,507 10,082 2,176 1,518 62,914 35,603 19 12 
enterocolitis 12,883 5,327 1,610 1,245 15,440 7,925 67 52 
pancolitis 505 283 25 18 1,187 913 0 0 
proctitis 2,916 849 80 60 5,526 2,579 9 5 
proctocolitis 644 124 6 3 1,194 310 1 1 
³toxic megacolon´ 626 180 30 18 1,447 593 1 1 
ulcerative 40,798 14,364 2,090 1,412 67,880 31,699 467 104 
Ileitis 3,285 637 37 31 6,056 2,639 14 1 
Enteritis 12,973 2,820 215 151 59,054 32,555 39 16 
³Inflammatory bowel´ OR Colitis OR 
³Crohn disease´ OR enterocolitis OR 
pancolitis OR proctitis OR proctocolitis OR 
³toxic megacolon´ OR ulcerative OR Ileitis 
OR Enteritis 
PUT ALL THE LIMITED ABSTRACTS 
FOUND FOR THIS SEARCH INTO 1 
DOCUMENT (17,7/('³,%'´ 
113,846 45,888 7,774 5,765 196,500 100,359 1,091 484 
  
 Ebscohost Medline CINAHL Embase PsychINFO 
IBD KEY WORDS FULL (N) Limited (N) FULL (N) Limited (N) FULL (N) Limited (N) FULL (N) Limited (N) 
PSYCH KEY WORDS         
³GHSUHVV* disorder*´ 78,299 35,515 2,570 1,976 31,646 21,116 18,457 11,111 
³Gepressive disorder, major´ 17,628 12,975 5 3 59 45 25 14 
³major depressive disorder´ 13,134 9,620 1,535 627 17,803 13,863 10,930 7,371 
depression 277,941 122,160 63,520 44,490 468,859 246,765 159,620 76,946 
³depress* symptoms´ 29,165 21,626 8,743 6,841 37,108 28,174 25,219 17,331 
³DGMXVWPHQWGisorder´ 728 353 128 82 3,581 1,758 715 300 
³Dnxiety disorder*´ 33,588 18,717 4,843 3,743 59,467 43,435 41,613 22,692 
³anxiety symptoms´ 4,309 3,218 879 728 5,743 4,340 4,260 2,920 
anxious 11,540 6,072 1,982 1,228 16,360 8,712 12,979 5,631 
anxiety 154,128 77,237 32,762 22,496 236,096 137,136 133,489 61,941 
³Sanic disorder´ 8,786 3,592 1,217 749 9,797 4,174 7,871 2,716 
OCD 6,268 3,988 649 442 8,885 5,993 5,980 3,640 
³obsessive-compulsive disorder´ 13,086 5,909 2,050 1,428 20,685 12,845 10,236 5,206 
³Shobic disorder´ 90 17 10 2 123 34 103 14 
³Pood disorder*´ 19,879 11,284 1,425 1,052 38,786 28,861 8,306 6,660 
³Vocial anxiety´ 3,459 2,558 560 448 4,555 3,328 4,980 3,141 
hypochondriasis 2,583 454 221 115 4,500 1,314 1,631 370 
PTSD  13,573 9,824 3,045 2,409 18,070 13,307 15,774 9,724 
³SRVWWUDXPDWLFVWUHVV´ 6,846 4,739 1,998 1,385 9,624 6,686 5,483 3,707 
³SRVWWUDXPDWLFVWUHVV´ 12,185 8,579 2,763 2,173 37,680 25,638 19,577 12,009 
distress 85,743 40,387 20,439 13,559 139,805 77,110 34,666 19,067 
³GHSUHVV* disorder*´25³GHSUHVVLYHGLVRUGHU
PDMRU´25³PDMRUGHSUHVVLYHGLVRUGHU´25
GHSUHVVLRQ25³GHSUHVVV\PSWRPV´25
³DGMXVWPHQWGLVRUGHU´25³DQ[LHW\GLVRUGHU*´
25³DQ[LHW\V\PSWRPV´25DQ[LRXV25
DQ[LHW\25³SDQLFGLVRUGHU´252&'25
³REVHVVLYH-FRPSXOVLYHGLVRUGHU´25³SKRbic 
GLVRUGHU´25³PRRGGLVRUGHU´25³VRFLDO
DQ[LHW\´25K\SRFKRQGULDVLV25376'25
³SRVWWUDXPDWLFVWUHVV´25 ³SRVWtraumatic 
VWUHVV´25GLVWUHVV 
PUT ALL THE LIMITED ABSTRACTS 
FOUND FOR THIS SEARCH INTO 1 
DOCUMENT (17,7/('³36<&+´ 
502,723 221,825 105,400 72,118 767,079 400,915 295,610 139,258 
  
Ebscohost Medline CINAHL Embase PsychINFO 
IBD KEY WORDS FULL (N) Limited (N) FULL (N) Limited (N) FULL (N) Limited (N) FULL (N) Limited (N) 
COMBINED KEY WORDS         
(³Inflammatory bowel´ OR Colitis OR 
³Crohn disease´ OR enterocolitis OR 
pancolitis OR proctitis OR proctocolitis OR 
³toxic megacolon´ OR ulcerative OR Ileitis 
OR Enteritis) AND (³GHSUHVV* disorder*´
25³GHSUHVVLYHGLVRUGHUPDMRU´25
³PDMRUGHSUHVVLYHGLVRUGHU´25GHSUHVVLRQ
25³GHSUHVVV\PSWRPV´25³DGMXVWPHQW
GLVRUGHU´25³DQ[LHW\GLVRUGHU*´25
³DQ[LHW\V\PSWRPV´25DQ[LRXV25
DQ[LHW\25³SDQLFGLVRUGHU´252&'25
³REVHVVLYH-FRPSXOVLYHGLVRUGHU´25
³SKRELFGLVRUGHU´25³PRRGGLVRUGHU´
25³VRFLDODQ[LHW\´25K\SRFKRQGULDVLV
25376'25³SRVWWUDXPDWLFVWUHVV´25
³SRVWWUDXPDWLFVWUHVV´25GLVWUHVV) 
 
PUT ALL THE LIMITED ABSTRACTS 
FOUND FOR THIS SEARCH INTO 1 
DOCUMENT (17,7/('³,%'$1'
36<&+´ 
 
 
ALSO PUT ALL REFERENCES FOUND 
INTO AN ENOTE FILE 
1,840 891 266 197 5,498 3,812 230 85 
 
 
Table 2. Summary characteristics of the studies addressing controversy 1: Are rates of anxiety/depression in IBD similar or different to that reported for the 
healthy/general population controls? (special populations indicated in grey) 
 
Authors, year, 
country and 
quality score 
Study information 
Design; setting; 
recruitment 
Participant 
characteristics (sample 
size, IBD type, 
median/mean age and 
age range, sex) 
Measures of 
anxiety, depression, 
disease activity  
Results  
Berrill et al. 2013 
(15) 
 
UK   
 
Quality: 8/14  
cross sectional; IBD 
adult outpatients 
attending 
gastroenterology 
hospital-based clinics; 
healthy controls from 
local advertising 
IBD: 150 participants 
(36%  CD) mean age 
45.7 (11.3), 63% female   
 
Controls: 41 healthy 
individuals, mean age 
43.8 (13.4), 61% female 
 
Anxiety: Hospital 
Anxiety and 
Depression Scale ±
Anxiety (HADS-A) 
 
Depression: HADS-D 
 
Disease activity: faecal 
calprotectin 
Anxiety: IBD median=9, range 1-20 
               Healthy Controls median=5, range 0-14 
               HC< IBD, p<0.001 
 
Depression: IBD median= 5, range 0-16 
                    Healthy Controls median=2, range 0-8 
                    HC< IBD, p<0.001 
 
 
Bessissow et al 
2013 (16) 
 
Belgium 
 
Quality: 6/14 
case-control; IBD 
recruited from tertiary 
care centre database if 
having colonoscopy; age 
and sex matched non-
IBD controls from 
electronic record 
database having 
colonoscopy; 
measured before and 
during colonoscopy 
IBD: 100 participants 
(63% CD); median age 
40 (IQR 31-49), range 
19-66, 52% female 
 
Controls: 100 non-IBD 
participants, median age 
41 (IQR 31-51), 52% 
female 
Anxiety: State-trait 
Anxiety Inventory ±
State (STAI-S), 
HADS-A 
 
Depression: HADS-D 
 
Disease activity: 
endoscopy 
Anxiety (STAI-S) before colonoscopy:  
                  IBD median=41.5, IQR 34-49.5;  
                 Controls median 39.0, IQR 30.5-49.5, p=ns 
 
Anxiety (HADS-A):  
                 IBD median=6, IQR 3-9 
                 Controls median=5 IQR=2-8, p=.09 
 
Depression (HADS-D):  
                  IBD median =5, IQR 4-7,  
                  Controls median=4, IQR 3-5.5 p=.01 
Calsbeek et al 
2006 (17) 
 
The Netherlands 
 
Quality: 5/14 
cross sectional; 
adolescents and young 
adults; IBD recruited via 
medical specialists in 
academic and specialized 
hospitals; diagnosis at 
least 6 months; controls 
recruited from patient 
files of 173 general 
practitioners who were 
IBD: 305 participants,  
mean age 20 (3.7); 
54.8% females  
 
Controls: 306 non-IBD 
participants from same 
GP practices; mean age 
18.5 (3.9); 54.9% 
females 
 
Anxiety: HADS-A 
 
Depression: HADS-D 
 
Disease activity ± not 
measured  
Anxiety: IBD mean =5.0 (3.8);  
               Controls mean=4.3 (3.0); p=ns 
 
Depression:  IBD mean=2.8 (2.9) 
                    Controls mean=2.6 (2.5) p=ns 
 
also GPs of chronic 
disease participants  
Calvet et al. 2006 
(18) 
 
Spain 
 
Quality: 9/14  
case-control; 
consecutive IBD patients 
treated with 
azathioprine or 6-
mercaptopurine; 
healthy controls age and 
sex-matched 2:1, 
recruited from families 
of patients at ambulatory 
surgery facilities for 
minimally invasive 
procedures.  
 
IBD: 33 CD participants 
with inactive IBD mean 
age =35.1 (SD 9.8), 9% 
female 
 
14 CD participants with 
active disease  mean 
age= 34.2 (SD 11.1), 
93% female 
 
Controls: 66 healthy 
individuals  mean age= 
34.7 (SD 9.4), 54% 
female 
  
 
Anxiety: Hamilton 
Anxiety and 
Depression ±Anxiety 
(HAM-A) 
 
Depression: HAM-D  
 
Cut-off score for severe 
anxiety=15; for major 
depression =18 
 
Disease activity: 
Harvey Bradshaw 
Index (HBI) 
Anxiety:      Inactive CD mean=6.45 (SD 5.4) 
                    Active CD mean=16.2 (SD 6.8) 
                    Controls mean=5.48 (SD 4.9) 
                    Active CD>inactive CD/controls p<0.01;  
Depression: inactive CD mean=3.73 (SD 3) 
                    Active CD mean=10.86 (SD 5.9) 
                    Controls  mean=3.26 (SD 3.6),  
                    Active CD>inactive CD/controls p<0.01;  
 Anxiety: proportion above cut-off 
                    Inactive CD 9.1% 
                    Active CD 71.4% 
                    Controls 7.6% 
Depression: proportion above cut-off 
                    Inactive CD 0% 
                    Active CD   14% 
                    Controls      1.5% 
Cotton et al. 2009 
(19)   
 
USA 
 
Quality: 5/14 
cross-sectional ; 
adolescents; IBD 
patients recruited from 
hospital IBD clinic and 
university hospital; 
controls recruited from 
hospital teen health clinic 
IBD: 67 participants; 
CD=52, UC=13, 
indeterminate=2; mean 
age=15.5 (1.98; range 
11-19), 55% female 
 
Controls: 88 healthy 
individuals; mean 
age=14.8 (1.9; range 11-
18 ), 43% female 
Anxiety: not measured 
 
'HSUHVVLRQ&KLOGUHQ¶V
Depression Inventory- 
short form (CDI, 10 
item)  
 
Disease activity: 
Lloyd-Still and Green 
score 
 
 
Depression: IBD       mean=2.46 (SD 2.82) 
                   Controls mean=1.68 (SD 2.22) p=0.04  
 
 
 
Goodhand et al. 
2012 (20) 
 
UK 
 
Quality: 6/14 
cross-sectional; IBD 
patients recruited from 
tertiary referral centre; 
controls recruited from 
healthy volunteers 
attending the 
hospital for an unrelated 
research study 
IBD: 204 IBD 
participants, 103 UC 
mean age 42.1 years (SD 
14.2), 59% female, 72% 
Caucasian, 38% active 
disease; 101 CD mean 
age 42.8 years (SD 14.3), 
57% female, 88% 
Caucasian, 27% active 
disease 
 
Anxiety: HADS-A 
 
Depression: HADS-D 
 
Cut-off score  > 7 
 
Disease activity: 
Simple Clinical Colitis 
Activity Index 
(SCCAI), 
sigmoidoscopy, 
Anxiety: inactive UC mean=7.8 (SD 3.5) 
               inactive CD mean=8.1 (SD 3.7)  
               active UC    mean=9.7 (SD 4.7) 
               active CD    mean=9.7 (SD 3.7) 
               Controls      mean=3.2 (SD 1.8) 
         Inactive UC/CD=Active CD/UC > controls p<0.0001 
 
Depression: inactive UC mean =3.3 (SD 2.4) 
                    inactive CD mean=4.2 (SD 3.6) 
                    active UC    mean= 6.1 (SD 3.6) 
                    active CD    mean=5.6 (SD 2.3) 
Controls:  124 healthy 
individuals, mean age 
28.7 years (SD 8.3), 43% 
female, 74% Caucasian 
&URKQ¶V'LVHDVH
Activity Index (CDAI),  
faecal calprotectin 
                    controls       mean= 1.7 (SD 1.4) 
         Inactive UC/CD=Active CD/UC > controls p<0.0001 
 
 
Lerebours et al 
2007 (21) 
 
France 
 
Quality: 11/14 
population-based case-
control; recruited newly 
diagnosed IBD patients 
(< 6 months) from IBD 
registry of 1009 incident 
IBD cases; healthy 
controls recruited from 
blood donor clinics in the 
same area and time 
period, with no GI 
disease history 
IBD: 241 IBD 
participants; 167 CD, 
mean age 32.3 (SD 13.1), 
62% female; 74 UC , 
mean age 36.1 (SD 15.1), 
50% female  
 
Controls: 255 blood 
donor individuals, mean 
age 37.1 (SD 11.9), 51% 
female 
 
 
Anxiety: Bates Anxiety 
Scale 
 
Depression: Beck 
Depression Inventory- 
short (BDI, 13 items) 
cut-off  score > 4 
 
 
Disease activity: 
unspecified 
Anxiety: CD         mean=52.22 (25.19) 
               UC         mean=40.31 (21.65) 
              Controls: mean=37.09 (21.28) 
              CD>UC=controls p<0.0083 
 
Depression:  CD mean=7.41 (5.87) 
                     UC mean =6.13 (4.93) 
                     Controls mean=4.40 (4.18) 
                     CD & UC > controls p<0.0083 
 
Depression: proportion above cut-off 
                     CD=61% 
                     UC=57% 
                     Controls=38% 
Loftus et al. 2011 
(22) 
 
USA 
 
Quality: 12/14 
retrospective cohort; 
youth; IBD and nonIBD 
age and sex-matched 
cases taken from national 
database of health 
service claims data for 
approximately 100 third-
party payers, including 
employers and health 
plans; observations from 
minimum of 6 months to 
a 6.5 years  
IBD: 2,144 CD cases  
 
Controls: 10,720 non-
IBD cases  
 
Both groups: mean age at 
index date 11.8 years,  
(SD N/A) ,46.1% female 
 
 
Anxiety: ICD 9 CM 
codes 293.84, 300.0x, 
313.0x (includes 
anxiety states and 
disorder) 
 
Depression: ICD 9 CM 
codes 296.2x, 296.3x, 
298.0x, 300.4x, 309.1x, 
311.xx (includes major 
depressive disorder, 
depressive type 
psychosis, dysthymia) 
 
Disease activity: based 
on treatment history 
 
Anxiety:  
         CD incident rate=1.81 cases per 100 patients years 
         Controls incident rate= 0.57 cases; p<0.0001  
           
Depression:  
          CD incident rate=2.69 cases per 100 patient years 
          Controls incident rate=1.22 cases; p<0.0001 
 
Mackner & 
Crandall 2005 
(23) 
 
cross sectional; 
adolescents;  
IBD patients identified 
from a clinic schedule 
IBD: 50 IBD 
participants, mean 
age=14.69 (SD 1.92), 
38% female, 80% 
Anxiety: Revised 
Manifest Anxiety Scale 
(RMAS)  
 
Anxiety: IBD      mean= 45.26 (SD 11.51) 
               Control mean=44.12 (SD 10.65); p=n.s. 
 
Depression: IBD      mean=42.86 (SD 7.36) 
USA 
 
Quality: 7/14 
review and chart review. 
Controls recruited from 
ambulatory clinics and 
hospital employee 
families.  
Caucasian  
 
Controls: 42 healthy 
individuals, mean age 
14.08 (SD 2.05), 48% 
female, 79% Caucasian 
 
Age range 11-17  for 
both groups 
Depression: CDI 
 
Cut-off score for each 
>66 
 
Disease activity: 
3DHGLDWULF&URKQ¶V
Disease Activity Index 
(PCDAI) 
                    Control mean=44.24 (SD 8.80); p=n.s. 
 
Anxiety: proportion above cut-off 
                     IBD =2% 
                    Controls=5% 
 
Depression: proportion above cut-off 
                     IBD=0% 
                     Controls=2 
Piche et al 2010 
(24) 
 
France 
 
Quality: 7/14 
cross sectional; CD in 
remission; 
IBD patients recruited 
from 5 university 
hospitals; healthy 
controls recruited from 
patients having screening 
colonoscopy (i.e., family 
history, and no GI 
symptoms) 
IBD: 92 participants, 
mean age 35.9 (SD 12.3), 
59% female 
 
Controls: 20 individuals, 
mean age 38.1 (SD 7.3), 
65% female 
 
 
Anxiety: HADS-A 
 
Depression: BDI-S 
 
Disease activity: CDAI 
plus haemoglobin, 
CRP, ESR, platelet 
count, albumin 
Results stratified by CD with and without IBS-type 
symptoms  
 
Anxiety:   
       CD with IBS-type symptoms      mean = 8.7 (SD 3.9), 
       CD without IBS-type symptoms mean =8.5 (SD 3.4) 
       Controls                                       mean=4.5 (SD 3.0) 
             CD with IBS-type > controls p=0.004 
 
Depression:  
       CD with IBS-type symptoms     mean=6.4 (SD 5.6) 
       CD without IBS-type symptoms mean=4.2 (SD 3.9) 
       Controls                                       mean=1.7 (SD 2.4) 
              CD with IBS-type>controls p=0.001 
              CD with IBS-type>CD without IBS-type p=0.02 
Reed-Knight et 
al. 2014 (25) 
 
USA 
 
Quality: 5/14 
prospective cohort 
study; adolescents; IBD 
patients recruited from 
IBD research registry at 
1 (US) of 24 US and 
Canadian sites; controls 
from community sample 
data from a different 
study with similar age, 
ethnicity and geographic 
region  
IBD: 78 participants, 
79% CD, 21% UC 
(mostly inactive/mild 
disease activity); mean 
age=13.79 (SD 2.79), 
49% female 
 
Controls: 564 non-IBD 
individuals, mean age 
12.43 (SD 0.87), 51% 
female  
Age range 8-17.5 years 
 
Anxiety: not measured  
 
Depression: CDI (27 
items)  
 
Cut-off score 
(conservative)=12 
Disease activity: 
abbreviated PCDAI 
 
Depression: IBD mean=4.83 (SD 4.90) 
                    Controls mean=6.08 (SD 5.79); p=0.03 
 
Depression: proportion above cut-off 12 
                    IBD=13%;  
                   Controls=proportion not available 
 
Van Langenberg 
& Gibson 2014 
cross-sectional; 
consecutive patients who 
IBD: 181 CD 
participants, median age 
Anxiety: HADS-A 
 
Anxiety:  CD median= 8 
                UC median=7 
  
 
 
 
 
(26) 
 
Australia 
 
Quality: 6/14 
attended a hospital IBD 
clinic, invited in person 
at a clinic visit or 
through phone; 
age- and sex-matched 
cohort of healthy 
subjects consecutively 
recruited through local 
advertisement  
41 years (range 18±68), 
54% female, 113 UC 
patients mean age 50 
years, 55% female   
 
Controls: 85  
healthy volunteers mean 
age 38 years, 69% 
female  
Depression: HADS-D  
 
Disease activity: HBI, 
SCCAI 
                Controls median=4 
(p<0.01) 
 
Depression: CD median=8 
                    UC median=7 
                    Controls median=2 
 (p<0.01) 
Walker et al. 
2008 (9) 
 
Canada 
 
Quality: 11/14 
population-based 
cohort; recruited from 
province-wide university 
IBD research registry, 24 
months into cohort data 
collection; control cases 
obtained from national 
health survey and age, 
gender and region-
matched  
 
 
IBD: 351 participants, 
mean age=43 years (SD 
14.06), 60% female, 95% 
Caucasian, 48% CD, 
46% UC/ulcerative 
proctitis, 6% 
indeterminate colitis.  
 
Controls: 779 cases, 
mean age=40 years (SD 
14.51), 59.1% female 
Anxiety: 12 month and 
lifetime prevalence of 
anxiety disorders 
assessed by 
Comprehensive 
International 
Diagnostic Interview 
(CIDI);  
 
Depression: 12 month 
and lifetime prevalence 
of mood disorders 
assessed by CIDI 
 
Disease activity: 
Manitoba IBD index 
(MIBDI)  
Anxiety: lifetime prevalence 
       Social anxiety 
                  IBD 6% 
                  Controls 11%;  OR 0.52, 95% CI 0.32±0.85 
       Panic Disorder 
                   IBD 8.0% 
                   Controls 4.7%;  OR 1.59, 95% CI 0.96±2.63 
      Agoraphobia without panic  
                   IBD  1.1%  
                   Controls 0.6%; OR 1.44, 95% CI 0.37±5.55 
 
Depression: lifetime prevalence 
       Major depression 
                    IBD 27.2% 
                    Controls 12.3%; OR 2.20, 95% CI 1.64±2.95 
Table 3. Summary characteristics of the studies addressing controversy 2: Are rates of anxiety/depression similar or different during inactive versus active disease? 
(special populations indicated in grey) 
 
Authors, year 
and country 
Study 
information: 
Design; setting; 
recruitment 
Participant 
characteristics 
(sample size, IBD 
type, age, sex) 
Measures 
anxiety, depression, disease 
activity 
Results  
Addolorato et al. 
2008 (27) 
 
Italy 
 
Quality: 7/15 
cross-sectional; 
consecutively 
recruited IBD 
outpatients from 
internal medicine 
outpatient setting 
135 IBD participants, 
948 (57.8%) female 
 
Active: 53 UC mean 
age=34 years (SD 
12.7); 41 CD mean 
age=36.6 years (SD 
14.5) % female N/A 
 
Inactive: 21 UC mean 
age=37.5 years (SD 
11.1); 20 CD mean 
age=40.6 (SD 12.9) % 
female N/A 
 
Anxiety: STAI 
Cut-off score =40 
 
Depression: Zung Self-
Rating Depression Scale 
(Zung SDS)  
Cutoff score  >49 
 
Disease activity: CDAI, 
Truelove-Witts Index 
(TWI), cut-off N/A 
Anxiety: proportion above cut-off  
              State- UC active  92.4% 
                         UC inactive 66% 
                         CD active 87.8% 
                         CD inactive 55% 
                          
               Trait- UC active 47.1% 
                         UC inactive 47.6% 
                         CD active 58.5% 
                         CD inactive 35% 
                         
Depression: proportion above cut-off 
                        UC active 15% 
                        UC inactive 0% 
                        CD active 21.9% 
                        CD inactive 15%                         
Agostini et al. 
2010 (28) 
 
Italy 
 
Quality: 7/15 
case-control; 
members of a 
regional IBD 
association 
recruited  by mail; 
controls randomly 
selected from the 
general population 
307 IBD participants  
 
Active: none 
 
Inactive: 174 CD, 133 
UC, mean age=43.14 
years, 51% female  
 
 
Anxiety: Symptom Checklist 
questionnaire (SCL-90±R)  
 
Depression: SCL90-R 
Cut-off  score >/= 63 
 
Disease activity ± CDAI 
(cut-off >/=150), Clinical 
Activity Index (CAI) (cut-
off >/= 2) 
Anxiety: proportion above cut-off 
               IBD active ± n/a  
               IBD inactive 10.9%  
                
 
Depression: proportion above cut-off 
               IBD active-n/a  
               IBD inactive 12.7% 
                
 
Banovic et al. 
2010 (49) 
 
France 
 
Quality: 6/15 
prospective 12-
month observation; 
recruited 
outpatients from a 
Parisian hospital 
experiencing 
52 CD participants 
 
Active: none 
 
Inactive: 52, mean age 
=41.21 (SD 12.54 
Anxiety: HADS-A 
 
Depression: HADS-D 
 
Disease activity: CDAI (cut-
off >/=150) 
Anxiety: (baseline) 
               IBD active n/a  
               IBD inactive mean=7.42 (SD 4.77) 
               (12 months) 
               IBD active n/a 
               IBD inactive mean=7.07 (SD 4.55) 
fatigue and no 
comorbid 
rheumatoid or 
peripheral arthritis. 
years), 27% female                  
Depression:  (baseline) 
               IBD active n/a  
               IBD inactive mean= 4.61 (SD 3.51) 
                
               (12 months) 
               IBD active n/a  
               IBD inactive mean= 3.5 (SD 3.26)                
Bennebroek 
Evertsz et al. 2012 
(29) 
 
The Netherlands 
 
Quality: 6/15 
cross-sectional; 
consecutive 
outpatients 
attending a tertiary 
care centre. 
231 IBD participants,  
59.7% CD, mean 
age=43.4 (SD 13.8, 
range 18-78),  56.3% 
female 
 
Active: 32  
Inactive: 157  
Anxiety: HADS-A 
 
Depression: HADS-D 
Cut-off score >/=8 for both 
 
Disease activity: HBI (cut-
off >6) and TWI (cut-off >6) 
Anxiety: proportion above cut-off 
               IBD active 56.3%  
               IBD inactive 31.8% (OR=2.72 | 95% CI: 
1.14±6.52 | p=0.024) 
 
Depression: proportion above cut-off 
              IBD active  41.9%  
              IBD inactive 21.1% (OR=3.36 | 95% CI: 
1.38±8.21 | p=0.008). 
Bitton et al. 2008 
(30) 
 
Canada 
 
Quality: 9/15 
prospective 
cohort; 12 month 
observation; 
consecutively 
recruited from  
university 
health centre and 
general hospital 
101 CD patients (60 
females, aged 33.6 
(SD=12.9) years) 
 
Active: 37  
Inactive: 64 
Anxiety: SCL90R 
 
Depression: SCL90R 
 
Disease activity: CDAI (cut-
off >/=150) , CRP, ESR, 
cytokines 
Anxiety: IBD active mean=0.58 (SD 0.62) 
               IBD inactive mean=0.43 (SD 0.56); p=0.25. 
 
Depression: 
              IBD active mean= 0.86 (SD 0.76)  
              IBD inactive mean= 0.57 (SD 0.50); p=0.10 
 
 
Calvet et al. 2006 
(18) 
 
Spain 
 
Quality: 9/15 
case-control; 
consecutive IBD 
patients treated 
with azathioprine 
or 6-
mercaptopurine; 
healthy controls age 
and sex-matched 
2:1, recruited from 
families of patients 
at ambulatory 
surgery facilities for 
minimally invasive 
procedures.  
47 CD participants 
 
Active: 14, mean age= 
34.2 (SD 11.1), 93% 
female 
Inactive: 33, mean age 
=35.1 (SD 9.8), 55% 
female  
 
 
Anxiety: Hamilton Anxiety 
and Depression ±Anxiety 
(HAM-A) 
 
Depression: HAM-D  
 
Cut-off score for severe 
anxiety=15; for major 
depression =18 
 
Disease activity: Harvey 
Bradshaw Index (HBI) (cut-
off > 2) 
 
Anxiety:  CD active mean=16.2 (SD 6.8) 
                CD inactive mean=6.45 (SD 5.4) 
                Active >inactive p<0.01;  
 
Depression: CD active mean=10.86 (SD 5.9) 
                    CD inactive  mean=3.73 (SD 3) 
                    Active >inactive p<0.01;  
 
 Anxiety: proportion above cut-off 
                    CD active 71.4% 
                    CD inactive 9.1% 
 Depression: proportion above cut-off 
                    CD active   14% 
                    CD inactive 0%                    
 Camara et al. 2011 
(31) 
 
Switzerland 
 
Quality: 9/15 
prospective 
cohort; 18 months 
observation, 
recruited from 
regional hospitals, 
and private 
practices 
468 CD participants, 
mean age= 41.83 (SD 
14.42), 50.6% female 
 
Active: 106 
Inactive: 362 
Anxiety: HADS-A 
 
Depression: HADS-D  
 
Disease activity: CDAI 
(>/=100 points increase from 
baseline), need for 
aggressive treatment, 
complications 
Anxiety: CD active mean=8.82 (SD 4.45) 
              CD inactive mean=6.12 (SD 4.01); p<0.001 
 
Depression: CD active mean=5.97 (SD 4.28)  
                   CD inactive mean=3.81 (SD 3.68); 
p<0.001 
 
 
Diaz Sibaja et al. 
2007 (32) 
 
Spain 
 
Quality: 5/15 
randomised 
controlled trial;  
baseline data 
reported  
57 IBD participants, 
34 CD, 23 UC 
 
Active: none 
Inactive: 57 
Anxiety: HADS-A, SCL90R 
 
Depression: BDI (cut-off 
>9), HADS-D (>/= 8), SCL-
90-R (no cut-off) 
 
Disease activity: unreported 
Anxiety:  
      Treatment, inactive IBD  
                            HADS-A mean=9.62 (SD N/A) 
                            SCL90-A  mean=1.07 (SD N/A) 
      Control, inactive IBD  
                            HADS-A  mean= 6.36 (SD N/A) 
                            SCL90-A mean= 0.75 (SD N/A) 
 
Depression:  
      Treatment, inactive IBD  
                            BDI mean=13.9 (SD N/A) 
                            HADS-D mean= 6.30 (SD N/A) 
                            SCL90-A  mean=1.51(SD N/A) 
      Control, inactive IBD  
                            BDI mean=7.71 (SD N/A) 
                            HADS-D mean= 4.36 (SD N/A) 
                            SCL90-D mean= 0.81(SD N/A) 
 
Anxiety, proportion above cut-off  
        Treatment, inactive IBD  HADS-A 35.3% 
                                                 SCL90R-A 50% 
Depression, proportion above cut-off 
        Treatment, inactive IBD  
                          BDI moderate 20.6%, severe 5.9% 
                          HADS-D 17.6% 
                          SCL90-D 55.9% 
 
Farrokhyar et al. 
2006 (33) 
 
Canada 
 
Quality: 8/15 
cross-sectional;  
consecutively 
recruited from 
university 
ambulatory 
gastroenterology 
clinic  
361 IBD participants 
 239 CD, 122 UC 
 
Active: 212; other data 
N/A 
Inactive: 149;  77 aged 
<40 years, 54% female 
Anxiety: HADS-A 
 
Depression: HADS-D 
 
Cut-off score  >7 for both 
 
Disease activity: 
Modified/Simplified Disease 
Activity Index (DAI) (cut-
off N/A) 
Anxiety: proportion above cut-off 
                IBD inactive 20.9%  
                CD inactive 29.8% 
                UC inactive 20.5% 
 
Depression: proportion above cut-off 
                IBD inactive 3.4%  
                CD inactive 7.7% 
                UC inactive 13.6% 
 
Anxiety & Depression:  
                IBD inactive 6.1% 
                CD inactive N/A 
                UC inactive N/A 
 
Data for active IBD N/A 
Gandhi et al. 2014 
(34) 
 
USA 
 
Quality: 5/15 
cross-sectional;  
recruited from the 
GI/IBD and 
infusion university 
clinics during a 
regularly scheduled 
visit 
70 IBD participants, 
69% CD, mean age 
43.26 years (SD 
16.50), 59% female, 
73% Caucasian  
 
Active: 18 
Inactive: 43 
(does not add up to 70, 
some data missing) 
Anxiety: not measured 
 
Depression: BDI  
 
Disease activity: HBI, 
modified HBI (cut-off >/= 5) 
 
Depression:  
              IBD active mean=16.4 (SD 9.9) 
              IBD inactive mean= 6.4 (SD 6.0); p<.0.001 
Goodhand et al. 
2012 (20) 
 
UK 
 
Quality: 8/15 
cross-sectional; 
IBD patients 
recruited from 
tertiary referral 
centre; controls 
recruited from 
healthy volunteers 
attending the 
hospital for an 
unrelated research 
study 
 
204 IBD participants 
 
103 UC mean age 
42.1= years (SD 14.2), 
59% female, 72% 
Caucasian, 38% active 
UC; 101 CD mean age 
42.8=years (SD 14.3), 
57% female, 88% 
Caucasian, 27% active 
CD 
 
Active:  62  
Anxiety: HADS-A 
 
Depression: HADS-D 
Cut-off score  > 7 for both 
 
Disease activity: SCCAI 
(cut-RII!ZLWKD%DURQ¶V
sigmoidoscopic score >1), 
CDAI (cut-off >150),  faecal 
calprotectin (cut-off >50 
mg/kg) and/or CRP(cut-off  
>10 mg/L) 
 
Anxiety: UC active   mean=9.7 (SD 4.7) 
               CD active   mean=9.7 (SD 3.7) 
               UC inactive mean=7.8 (SD 3.5) 
               CD inactive mean=8.1 (SD 3.7)  
               Controls      mean=3.2 (SD 1.8) 
  Inactive UC/CD=Active CD/UC > controls p<0.0001 
 
Depression: UC active     mean= 6.1 (SD 3.6) 
                    CD active     mean=5.6 (SD 2.3) 
                    UC inactive mean =3.3 (SD 2.4) 
                    CD inactive mean=4.2 (SD 3.6) 
                    Controls       mean= 1.7 (SD 1.4) 
  Inactive UC/CD=Active CD/UC > controls p<0.0001 
Inactive:  142 
Graff et al. 2006 
(4) 
 
Canada 
 
Quality: 11/ 15 
population-based 
cohort; recruited 
from province-wide 
university IBD 
research registry  
 
356 IBD patients 
 
169 UC mean age= 
43.0 years (SD 14.7), 
58% female, 88% 
Caucasian; 187 CD 
mean age= 38.5 years 
(SD 14.6), 61% female, 
93% Caucasian 
  
Active: 109 UC; 135 
CD  
Inactive: 56 UC; 48 
CD 
Anxiety: Health Anxiety 
Questionnaire 
 
Depression: not measured 
 
Disease activity: MIBDI  
Active disease=symptoms 
daily-few days/month 
Anxiety:  UC active mean=15.07 (SD 9.16)  
                UC inactive mean=9.29 (SD 5.59); p=0.01 
 
               CD active mean=17.98 (SD 10.6)  
               CD inactive mean=11.85 (SD=7.70); p=0.01 
 
 
Horst et al. 2015 
(35) 
 
USA 
 
Quality: 10/15 
retrospective 
cohort; 
consecutively 
recruited from 
single tertiary care 
IBD 
69 IBD participants,  
16 UC, 53 CD, median 
age 33 years,  58% 
female 
 
Active: 69 active 
initially 
Inactive: some 
(n=N/A) became 
inactive during study 
 
Anxiety: not measured 
 
Depression: Patient Health 
Questionnaire-9 (PHQ-9)  
 
Cut-off score >/=10 
 
Disease activity: HBI, 
SCCAI (cut-off N/A) 
 
Depression: IBD active mean=12 (IQR 5,14  
                    IBD inactive mean=6 (IQR: 3, 14)  
                    p<0.05 
 
 
Iglesias et al. 2009 
(36) 
 
Spain 
 
Quality: 8/15 
cross-sectional; 
consecutively 
recruited from 
inflammatory 
bowel disease unit 
 
92 CD participants 
mean age=37 years 
(SD=11.4), 47.8% 
female 
 
Active: none 
Inactive: 92 
Anxiety: HADS-A 
 
Depression: HADS-D 
Cut-off score >/=8 for both 
 
Disease activity ± CDAI 
(cut-off >/=150), HBI (cut-
off >3), CRP (cut-off >5 
mg/L) 
Anxiety: proportion above cut-off 
               CD inactive 39% 
 
Depression: proportion above cut-off 
                CD inactive 24% 
 
Jedel et al. 2013 cross-sectional; 50 UC participants Anxiety: STAI Anxiety: UC mild active mean=35.37 (SD 8.72)  
(37) 
 
USA 
 
Quality: 6/15 
recruited from 
university medical 
centre 
mean age 42.2 years 
(SD 12.3), 62% female, 
78% Caucasian 
 
Active: none 
Inactive:  50 
 
Depression: BDI 
 
Disease activity: Mayo 
Score Disease Activity 
Index (MSDAI), 0=inactive, 
1-2=mild symptoms 
               UC inactive mean=40.74 (SD 14.17) 
               (p=n.s.) 
 
Depression: UC mild active mean=8.27 (SD 8.5)  
                    UC inactive mean=8.13 (SD 8.18) 
                    (p=n.s.) 
 
Kappelman et al. 
2014 (38) 
 
USA 
 
Quality: 6/15 
Cross-sectional 
and longitudinal; 
internet-based 
cohort  
recruited from IBD 
patient organisation 
10,634 IBD 
participants  (6689 CD, 
3945 UC or IC), mean 
= 44 years (SD 14.8), 
71% female  
 
Active: N/A 
Inactive: N/A 
 
Anxiety: PROMIS anxiety 
items 
 
Depression: PROMIS 
depression items 
 
Disease activity: CDAI-
short, SCCAI; active disease 
corresponds to a SCDAI of 
</=150 points or a score >2 
or an increase in SCCAI of 
>5 points. 
Anxiety: IBD mild active mean=52 (SD 9) 
               IBD moderate active mean=55 (SD 9) 
               IBD severe active mean=59 (SD 9) 
               IBD inactive mean=49 (SD 8) 
Depression: IBD mild active mean=50 (8) 
                    IBD moderate active mean= 53 (SD 9) 
                    IBD severe active mean=58 (SD 10) 
                    IBD inactive mean=47 (SD 7) 
 
                    all p <0.0001 
Kim et al. 2013 
(39) 
 
Korea 
 
Quality: 7/15 
cross-sectional; 
recruited from 5 
tertiary hospitals;  
age and sex-
matched healthy 
controls recruited  
from university 
health centre of 
those attending for  
routine medical 
check-up  
226 IBD participants  
107 CD , 119 UC, 
mean age =39.01  years 
(SD 15.63) years, 38% 
female  
 
Active: none 
Inactive: 226 
Anxiety: HADS-A 
 
Depression: HADS ±D 
Cut-off score >7 for both 
 
Disease activity:  CRP, ESR, 
haemoglobin, no new 
medications required or no 
change of dose required 
Anxiety:  proportion above cut-off 
                IBD inactive 27.4% 
 
Depression: proportion above cut-off 
               IBD inactive 33.6% 
 
Langhorst et al. 
2013 (40) 
 
Germany 
 
Quality: 8/15 
prospective; 12 
month observation, 
recruited through 
advertisements in 
local, regional 
newspapers and 
journal of IBD 
patient organisation 
75 IBD patients  
 
Active: 28, mean 
age=45.1 years (SD 
13.4), 32% female 
 
Inactive: 47, mean 
age=48.7 years (SD 
12.8) 57% female 
Anxiety: HADS-A 
 
Depression: HADS ±D 
Cut-off  score >7 for both 
 
Disease activity: CAI (cut-
off > 4 or an increase of 
>3 from baseline), patient 
diary, & sigmoidoscopy 
Anxiety:  
               IBD active N/A  
               IBD inactive N/A 
                
Depression:  
               IBD active mean=7.9 (SD=4.4)  
               IBD inactive mean =7.2 (SD 4) 
                
 
Depression: proportion above cut-off >7; >10 
                    IBD active  50%; 32.1% 
                    IBD inactive 49.6%; 23.4% 
                  (all p=n.s.) 
Larsson et al. 
2008 (41) 
 
Sweden 
 
Quality: 4/15 
cross-sectional; 
recruited from 
university hospital 
742 IBD participants 
mean age 45 years 
(range 19±65) 51% 
female 
 
Active: 166 
Inactive: 554 (does not 
add up to 742, some 
missing) 
Anxiety: HADS-A 
 
Depression: HADS-D 
Cut-off score  >7 for both 
 
Disease activity: yes/no 
questions 
Anxiety:  
             IBD active median=7.0 (IQR 5.0-10.0) 
             IBD inactive median=5.0 (IQR 1.0-8.0) 
(p<0.001) 
 
Depression:  
              IBD active  median=4.0 (IQR 2.0±7.0)  
             IBD inactive median=3.0 (IQR 1.0-5.0) 
(p<0.001)  
Lix et al. 2008 
(42) 
 
Canada 
 
Quality: 11/15 
population-based 
cohort; 24 month 
disease activity 
monitoring; 
recruited from 
province-wide 
university IBD 
research registry 
356 IBD participants 
187 CD, mean age= 
38.5 years (SD 14.6) 
61% female; 169 UC 
mean age= 43 years 
(SD 14.7), 59% female  
 
Active (consistently): 
109 
Inactive (consistently): 
60 
Fluctuating activity: 
174  
 
Anxiety: HAQ 
 
Depression: not measured  
 
Disease activity: MIBDI 
Active disease=symptoms 
daily-few days/month 
Anxiety: baseline; 24 months 
     CD consistently active mean=17.7 (SD 9.5);  
                                          mean=14.6 (SD 9.6)  
     CD fluctuating mean=16.7 (SD 10.9);  
                             mean=10.5 (SD 7.3)  
     CD consistently inactive mean=12.2 (SD 9.1);  
                                        mean=8.1 (SD 8.5)  
     
 
    UC consistently active mean=14.1 (SD 7.7);  
                                           mean=12.9 (SD 8.7)   
    UC fluctuating mean=14.1 (SD 9.4);  
                              mean=10.6 (SD 8.2)  
    UC consistently inactive mean=9.0 (SD 5.4);   
                                            mean=6.2 (SD 5.2) 
      
 consistently active> consistently inactive p<0.0001 
Long et al. 2014 
(43) 
 
 USA 
 
Quality: 6/15 
cohort, internet 
based; elderly (>/= 
65 years);  
recruited from  
IBD  patient 
organisation 
359 IBD participants 
mean age=70.2 years 
(SD 4.7) 62% female 
  
Active: N/A 
Inactive: N/A 
 
 
Anxiety: not measured 
 
Depression: Geriatric 
Depression Scale (GDS)  
Cut-off score   
 
Disease activity: CDAI , 
SCCAI, MIBDI (cut-offs 
N/A) 
 
 
Depression: proportion above cut-off 
    IBD active 28.9% 
    IBD inactive 15.1%; p=0.002 
     
Reigada et al. 
2014 (44) 
 
USA 
 
Quality: 7/15 
retrospective 
medical chart 
review; youth; 
recruited from 
paediatric 
gastroenterology 
practice (completed 
survey as part of a 
different study) 
93 CD participants 
mean age= 14.7 years 
(SD 2.1) age range 9-
18, 45% female 
 
Active: 4 
Inactive: 76 
Anxiety: Screen for Child 
Anxiety Related Disorders 
(SCARED); higher scores 
indicate higher anxiety 
Cut-off score >/=20 
 
Depression: not measured 
 
Disease activity: HBI (cut-
off >/=5) 
Anxiety:  
              CD active mean rank=67.6 
              CD inactive mean rank=39.0; p=0.01 
                
 
Simren et al. 2006 
(45) 
 
Sweden 
 
Quality: 8/15 
cross-sectional; 
recruited 
consecutive IBD 
and other GI 
patients 
attending a GI 
outpatient clinic  
223 IBD participants  , 
90 CD, 133 UC mean 
age=46 years (SD 0.9) 
years N/A % female 
 
Active: 82 
Inactive: 138 (does not 
add up to 223, some 
missing) 
Anxiety: Psychological 
General Wellbeing Index-A, 
anxiety and depression 
subscales 
 
Depression: Psychological 
General Wellbeing Index-D 
 (PGWBI: higher 
scores indicate better 
psychological well-being) 
 
Disease activity: CRP, ESR, 
platelets,  endoscopy, steroid 
use  
Anxiety: IBD active mean=21 (SD 4.8) 
               IBD inactive mean=23 (SD 4.7); p=0.004 
 
Depression: IBD active mean=14 (SD 3.3)  
                    IBD inactive mean=15 (SD 2.6); p=0.007 
 
 
 
Vidal et al. 2008 
(46) 
 
Spain 
 
Quality: 7/15 
cross-sectional;  
recruited 
consecutive patients 
attending 
IBD outpatient 
hospital-based 
clinic 
147 IBD participants  
76 CD, 71 UC mean 
age 37.2 years (range 
18-75), 51.7% female 
 
Active:  36 
Inactive:  111  
Anxiety: HADS-A 
 
Depression: HADS-D 
Cut-off  score >8 for both 
 
Disease activity: CDAI (cut-
off >/=150), TWI (cut-off 
>/=7) 
Anxiety: IBD active mean=7.1 (range 1-13) 
               IBD inactive mean=7.2 (range 0-21); p=n.s. 
 
Depression:  IBD active mean=3.8 (range 1-13)  
                     IBD inactive mean=3.7 (range 0-15); 
                     p=n.s. 
 
 
Zhang et al. 2013 
(47) 
 
USA 
 
Quality: 6/15 
cross-sectional; 
recruited from  
university IBD 
program during 
regularly scheduled 
outpatient clinic 
appointments 
105 IBD participants 
55 CD, 50 UC, mean 
age=33 ( SD 12.9)  
45.5% female,  
 
Active: 45 
Inactive: 60 
Anxiety: not measured 
 
Depression: BDI II cut-off 
>/=14 
BDI for Primary Care (BDI-
PC) cut-off score >/=4 
 
 
Depression: BDI-PC 
            CD active median = 12 (SD 8.89); 
                             median = 4 (SD 2.93) 
           CD inactive median = 8 (SD 6.60); 
                                Median =2 (SD 2.51) 
            UC active median = 10 (SD 8.66);  
Disease activity: CDAI cut-
off >/=150)6HR¶V$FWLYLW\
Index (SAI) (cut-off >/=120) 
                              median=2 (SD=2.86) 
            UC inactive median = 6 (SD 10.3); 
                                median = 1 (SD 3.69)    
Zimmerman et al. 
2013 (48) 
 
USA 
 
Quality: 8/15 
cross-sectional; 
youth; recruited 
from 2 hospitals for 
sub-study of a 
cognitive 
behavioural therapy 
trial 
307 CD participants, 
139 with abdominal 
pain;  mean age=14 
years (range 9-17), 
50.1% female 
 
Active: 151 
Inactive: 156  
Anxiety: not measured 
 
Depression: CDI 
Cut-off score >9 
 
Disease activity: P-CDAI 
(cut-off >10) 
 
Depression: proportion above cut-off 
                   CD active & abdominal pain 59 (49%)  
                   CD inactive & no abdominal pain 47 (30%) 
(p= N/A) 
                    
 
 
 
Table 4. Summary characteristics of the studies addressing controversy 3: Are rates of anxiety/depression similar or different in CD versus UC? (special populations 
indicated in grey) 
 
Authors, year 
and country 
Study information 
Design; setting; 
recruitment 
Participant characteristics 
(sample size, IBD type, 
age, sex) 
Measures 
anxiety, depression , 
disease activity  
Results  
Addolorato et al. 
2008 (27) 
 
Italy 
 
Quality: 6/12 
cross-sectional; 
consecutively 
recruited IBD 
outpatients from 
internal medicine 
outpatient setting 
135 IBD participants, mean 
age=43.9 years (SD 15.9), 
57.8% female 
 
UC: 74 
CD: 61 
 
 
 
Anxiety: STAI 
Cut-off score =40 
 
Depression: Zung Self-
Rating Depression Scale 
(Zung SDS)  
Cut-off score  >49 
 
Disease activity: CDAI, 
Truelove-Witts Index 
(TWI) 
 
 
Anxiety: proportion above cut-off  
              State- UC inactive 66% 
                         UC active  92.4% 
                         CD inactive55% 
                         CD active 87.8% 
               Trait-UC inactive 47.6% 
                        UC active 47.1% 
                        CD inactive 35% 
                        CD active 58.5% 
 
Depression: proportion above cut-off 
                        UC inactive 0% 
                        UC active 15% 
                        CD inactive 15% 
                        CD active 21.9% 
Ananthakrishnan 
et al. 2013 (51) 
 
USA  
 
Quality: 11/12 
prospective 
registry-based 
cohort; bowel 
resection surgery 
1237 IBD participants -no 
depression prior to surgery, 
mean age=48 years (SD 
N/A) , 47% female 
 
UC:  530 
CD: 707 
 
Anxiety: ICD9 codes for 
generalized anxiety 
(293.84, 300.0, 313.0) 
 
Depression: ICD-9 codes 
for depressive disorders 
(296.2, 296.3, 298.0, 311)  
 
Disease activity: 
complications,  
medications from medical 
chart 
Anxiety (risk following IBD-related surgery): 
               CD year 1: 7% 
               CD year 2: 9% 
               CD year 5: 14% 
               UC year 1: 7% 
               UC year 2: 10% 
               UC year 5: 12% 
 
Risk of anxiety post-surgery (compared to those 
without surgery) 
               CD (OR 1.20, 95% CI 0.93 ± 1.55)  
               UC (OR 1.26, 95% CI 0.96 ± 1.65). 
 
Depression (risk following IBD-related surgery): 
 
               CD year 1: 6% 
               CD year 2: 8% 
               CD year 5: 16% 
               UC year 1: 5% 
               UC year 2: 7% 
               UC year 5: 11% 
                
               UC=CD for risk of depression post-surgery 
                  (adjusted OR 1.11, 95% CI 0.84 ± 1.47)  
               Risk of depression post-surgery (compared to 
               those without surgery) 
               CD (adjusted OR 1.34, 95% CI 1.01 ± 1.77) 
               UC (OR 1.21, 95% CI 0.93 ± 1.58). 
 
Ananthakrishnan, 
et al. 2013 (52) 
 
 USA   
 
Quality: 10/12 
cross-sectional; 
cases from large 
multi-institution 
study using 
electronic medical 
record (EMR) 
10834 IBD cases 
 
UC: 5429, mean age=50.3 
years (SD 18.4), 58% 
female 
 
CD: 540, mean age=47.1 
years (SD 18.4), 57% 
female 
 
  
Anxiety: ICD9 codes for 
generalized anxiety 
(293.84, 300.0, 313.0) 
 
Depression: ICD-9 codes 
for depressive disorders 
(296.2, 296.3, 298.0, 311)  
 
Disease activity: 
complications, 
medications from medical 
chart 
Anxiety/Depression (reported combined) 
              UC: 19% prior to first surgery 
              CD: 18% prior to first surgery  
 
 
Bennebroek 
Evertsz et al. 
2012 (29) 
 
the Netherlands 
 
Quality: 5/12 
cross-sectional; 
consecutive 
outpatients 
attending a tertiary 
care centre. 
 
231 IBD participants, mean 
age=43.4 (SD 13.8 range 
18-78),  56.3% female 
 
UC: 93 
CD:  138 
 
 
Anxiety: HADS-A 
 
Depression: HADS-D 
Cut-off score >/=8 for both 
 
Disease activity: HBI and 
TWI  
Anxiety: proportion above cut-off 
              UC 25.0% 
              CD 44.9% 
(p=0.004) 
Depression: proportion above cut-off 
             UC 21.1%               
             CD 27.8%  
(p=0.329) 
Cohen at al. 2014 
(53)  
 
USA 
 
Quality: 8/12 
Population-based 
cohort; newly 
diagnosed IBD 
patients recruited 
from state-wide 
IBD registry  
220 IBD participants 
 
UC: 95, 44% between 18-
34 years, 57% female, 40% 
married 
 
CD: 125, 53% between 18-
34 years, 64% female, 38% 
married 
 
 
Anxiety: not measured 
 
Depression: PHQ-8  
Cut-off  >/=10 
 
Disease activity: HBI, 
SCCAI  
 
Results stratified by IBD type and fatigue 
 
Depression: proportion above cut-off 
             UC & fatigue 41.7% 
             CD & fatigue  42.3%  
             UC & nonfatigue 4.3% 
             CD & nonfatigue 6.4% 
 
Fatigued vs. Non-fatigues CD p<.001 
Fatigued vs. Non-fatigues UC p=.006 
 
Farrokhyar et al. 
2006 (33) 
 
Canada 
 
Quality: 7/12 
cross-sectional; 
recruited 
consecutively from 
university 
ambulatory 
gastroenterology 
clinic  
149 participants with 
inactive disease 52% aged 
<40 years, 54% female  and 
the analysis is provided for 
them 
UC: 144, 47.7% female 
CD: 105 , 57.1% female 
 
Anxiety: HADS-A 
 
Depression: HADS-D Cut-
off score >/=7 for both 
 
Disease activity: 
simplified Disease 
Activity Index (DAI) 
Anxiety:  proportion above cut-off 
                UC 20.5% 
                CD 29.8% 
(p=0.24) 
Depression: proportion above cut-off 
                UC 13.6% 
                CD 7.7%  
 (p=0.26) 
Goodhand et al. 
2012 (20) 
 
UK 
 
Quality: 5/12 
A cross-sectional 
study, IBD patients 
recruited at a 
tertiary referral 
centre, controls 
were healthy 
volunteers 
attending the 
hospital for an 
unrelated research 
study 
204 IBD participants 
UC: 103, mean age= 42.1 
years (SD14.2), 59% 
female, 72% Caucasian, 
38% active disease 
 
CD:  101 mean age= 42.8 
years (SD 14.3), 57% 
female, 88% Caucasian, 
27% active disease 
 
Anxiety: HADS ± cut-off 
> 7 
 
Depression: HADS ± cut-
off > 7 
 
Disease activity: CDAI 
and SCCAI, 
sigmoidoscopy, CRP 
Anxiety: 
             Active CD M=9.7, SD=3.7 
             Active UC M=9.7, SD=4.7 (p= n.s.) 
             Inactive CD M=8.1, SD=3.7 
             Inactive UC M=7.8, SD=3.5 (p= n.s.) 
Depression : 
             Active CD M=5.6, SD=2.3 
             Active UC M=6.1, SD=3.6 (p= n.s.) 
             Inactive CD M=4.2, SD=3.6 
             Inactive UC M=3.3, SD=2.4 (p= n.s.) 
 
Hauser et al. 
2011 (54) 
 
Germany 
 
Quality: 5/12 
A cross-sectional 
study, consecutive 
adult IBD patients 
attending three 
tertiary care centers 
for evaluation 
and/or therapy and 
members of 
the patient 
422 IBD participants  
 
UC: 108 (44.5 (SD=13.7), 
41.7% female) 
 
CD: 314 (aged 43.2 
(SD=11.0) years, 52.9% 
female) 
 
Anxiety: HADS ± cut-off 
>/=11  
 
Depression: HADS ± cut-
off >/=11 
 
Disease activity:  the 
German Inflammatory 
Bowel Disease Activity 
Anxiety: 
             CD M=7.4, SD=4.2 
             UC M=6.9, SD=3.6 (p=0.3) 
Depression: 
             CD M=5.1, SD=4.0  
             UC M=5.7, SD=3.8 (p=0.2) 
organisation, 
chronic liver 
disease patients  
attending one 
tertiary referral 
center, a random 
representative 
sample of German 
population 
 Index 
Herzog at al. 
2013 (55) 
 
Switzerland  
 
Quality: 5/12 
cross-sectional; 
adolescents; 
recruited as part of 
a prospective 
cohort study from 
regional hospitals, 
and private 
practices 
126 IBD participants 
 
CD: 71, mean age 13.4 
(SD=3.2), 38% female;  
 
UC/IC 55, mean age 12.8 
(2.7), 54% female 
 
Anxiety: not measured 
 
Depression: Child 
Depression Inventory 
(CDI) ± cut-off N/A 
 
Disease activity: PCDAI, 
PCAI 
Depression:  
              CD M=6.57, SD=6.5  
              UC/IC=6.67, SD=4.1 
Iglesias-Rey at 
al. 2012 (57) 
 
Spain 
 
Quality: 5/12 
cross-sectional; 
consecutive patient 
recruitment from 
the hospital IBD 
unit 
484 IBD participants 
 
CD: 192, mean age 38.3, 
58.3% female, 46.9% single  
 
UC: 292 mean age 47.0, 
49.3% female, 25.0% single 
Anxiety: HADS ± cut-off 
>11 
 
Depression: HADS ± cut-
off >11 
 
Disease activity: HBI, 
Mayo Index   
Anxiety: 
              CD M=4.73 (95% CI 4.14-5.34)  
              UC M=4.71 (95% CI 4.21-5.21) (p= N/A) 
 
Depression: 
              CD M=7.18 (95% CI 6.58-7.78) 
              UC M=7.34 (95% CI 6.79-7.88) 
Iglesias-Rey at 
al. 2014 (56) 
 
Spain  
  
Quality:5/12  
  
cross-sectional; 
consecutive patient 
recruitment from 
the hospital IBD 
unit  
793 IBD participants 
 
CD: 323, mean age 39.9, 
57.6% female, 45.2% 
single;  
 
UC: 470 mean age 47.8, 
49.8% female, 26.4% 
single  
Anxiety: HADS ± cut-off 
>/=11  
 
Depression: HADS ± cut-
off >/=11  
  
Disease activity: HBI, 
Mayo Index   
Anxiety: 
              CD M=4.84 (95% CI 4.39±5.92)  
              UC M=4.92 (95% CI 4.53±5.31) (p=N/A) 
 
Depression:  
              CD M=7.27 (95% CI 6.82±7.72)  
              UC=7.43 (95% CI 7.02±7.85) (p=N/A) 
Janke at al. 2006 
(58) 
 
Germany 
 
Quality: 6/12 
cross-sectional; 
consecutive patients 
recruited from  
tertiary care centres 
and members of 
patient organisation 
429 IBD participants 
 
CD: 317, mean age=43.2 
(SD=11.0), 52.7% female  
 
UC: 112, mean age=44.4 
(SD=13.6), 42.8% female 
Anxiety: HADS ± cut-off 
>/= 11 
 
Depression: HADS ± cut-
off >/= 11 
 
Disease activity:  German 
Inflammatory Bowel 
Disease Activity Index 
Anxiety: proportion above cut-off 
               CD 20.5%  
               UC 14.8% (p= N/A)  
 
Depression: proportion above cut-off 
               CD 9.3%  
               UC 13.0% (p= N/A) 
Kappelman et al. 
2014 (38) 
 
USA 
 
Quality: 4/12 
nested cross-
sectional; part of 
longitudinal 
internet-based 
cohort of 
patients with IBD 
recruited via a 
patient organisation 
10,634 IBD patients  44 
years, 71% female 
 
CD: 6689 
 
UC/IC: 3945 
Anxiety: The PROMIS, a 
minimally important 
difference between 2 and 6 
 
Depression: The PROMIS, 
a minimally important 
difference between 2 and 6 
 
Disease activity: CDAI 
(short), SCCAI 
Anxiety: 
               CD M=52, SD=10 
               UC/IC M=52, SD=9 (p= N/A) 
 
Depression:  
               CD M=54, SD=10 
               UC/IC M=54, SD=10 (p= N/A) 
Kim et al. 2013 
(39) 
 
Korea 
 
Quality: 5/12 
cross-sectional; 
IBD patients 
recruited from 5 
tertiary hospitals 
and healthy 
controls (matched 
for age and sex) 
from people who 
visited a university 
health promotion 
center for a routine 
medical check-up  
226 IBD participants with 
inactive IBD, mean age 
39.01 (SD=15.63) years, 
37% female 
 
CD: 107  
UC: 119,  
Anxiety: HADS ± cut-off 
>7 
 
Depression: HADS ± cut-
off >7 
 
Disease activity: CRP,  
ESR, Hb, no new 
medications required or no 
change of dose required 
Anxiety: proportion above cut-off and means (SD) 
               CD 30.8%, M=6.12 ± 3.89 
               UC 24.4%, M=4.97 ± 3.89 (p= n.s.) 
 
Depression: proportion above cut-off and means (SD) 
               CD 40.2%, M= 6.12 ± 3.58 
               UC 27.7% M=4.97 ± 3.53 (p = 0.05) 
 
  
Larsson et al. 
2008 (41) 
 
Sweden 
 
Quality: 4/12 
cross-sectional; 
patients attending a 
university hospital 
742 IBD participants, aged 
45 years, 51% female 
 
UC: 496  
CD: 246 
Anxiety: HADS ± cut-off 
>7 
 
Depression: HADS ± cut-
off >7  
 
Disease activity: yes/no 
questions 
Anxiety: 
              CD Median=8.0, IQR= 5.7-13  
              UC Median=6.0, IQR= 3.0-9.5 (p<.01) 
 
Depression: 
              CD Median=6.0, IQR= 2.0-9.0  
              UC Median =4.0, IQR= 1.0-6.0 (p<.05)  
Lerebours et al. 
2007 (21) 
 
France 
 
Quality: 9/12 
population-based 
case-control; 
recruited newly 
diagnosed IBD 
patients (< 6 
months) identified 
from an IBD 
registry; healthy 
controls recruited 
from blood donor 
clinics in the same 
area and in the 
same time period± 
no GI disease 
history 
241 IBD cases 
 
UC: 74, mean age 36.1 
(SD=15.1), 50% female  
 
CD: 167, mean age 32.3 
(SD=13.1), 62% female 
 
 
Anxiety: Bates Anxiety 
Scale ± cut-off N/A 
 
Depression: BDI ± cut-off  
> 4 
 
Disease activity: 
unspecified  
Anxiety: proportion above cut-off and means (SD 
               CD M=52.2+25.2,  
               UC M=40.31 ± 21.65 (p<.03) 
 
Depression: proportion above cut-off and means (SD) 
               CD 61%, M=7.41 ± 5.87 
               UC 57%, M=6.13 ± 4.93 (p<.14) 
 
Long et al. 2014 
(43) 
 
USA 
 
Quality: 5/12 
cohort;  
elderly patients 
recruited from a 
patient organisation 
359 IBD participants 
mean age=70.2 years (SD 
4.7) 62% female 
 
UC: 134  
CD: 224 
 
Anxiety: not measured 
 
Depression: Geriatric 
Depression Scale (GDS) ± 
cut-off  
 
Disease activity: CDAI, 
SCCAI, Manitoba IBD 
Index 
Depression: proportion above cut-off 
                CD 24.1% 
                UC 20.2% (p=n.s.) 
Pellissier et al. 
2010 (66) 
 
France 
 
Quality: 5/12 
cross-sectional; 
IBD patients 
recruited from 
hospital tertiary GI 
clinic; age and sex 
matched healthy 
controls from 
clinical 
investigation centre 
48 IBD participants; 
 
UC: 22, mean age=42 
(SD=16), 59% female 
 
CD: 26, mean age 43 
(SD=14), 69% female  
 
 
 
Anxiety: STAI ± cut-off 
N/A 
 
Depression: CES-D ± cut-
off N/A 
 
Disease activity: HBI, 
UCAI 
 
Anxiety : 
       State Anxiety 
                CD M=30.50 +/- 1 1.39  
                UC M=31.30 +/- 1.71 (p= N/A) 
       Trait Anxiety 
                CD M=35.85 +/- 1.60  
                UC 38.92 +/-2.03 (p= N/A) 
Depression: 
                CD M=7.71 +/- 1.22  
                UC 12.30 +/- 2.17(p= N/A) 
Rochelle and 
Fidler 2013 (59) 
 
UK 
 
Quality: 3/12 
cross-sectional; 
outpatients 
prospectively 
enrolled out of a 
gastroenterology 
department at a 
teaching hospital.   
102 IBD participants, mean 
age 41.9 years (SD = 
16.57), 65.7% female 
 
UC: 46 
CD: 56  
Anxiety: HADS ± cut-off 
>/=8 
 
Depression: HADS ± cut-
off >/=8 
 
Disease activity: blood 
tests 
Anxiety:  
               UC M=9, SD= N/A 
               CD M=8.68, SD = N/A (p= N/A) 
Depression: 
               UC M=6.93, SD= N/A 
               CD M=6.8, SD= N/A (p= N/A) 
Schuman at al. 
2013 (60) 
 
USA 
 
Quality: 4/12 
cross-sectional; 
youth; part of a 
larger longitudinal 
multisite 
assessment project, 
recruited at 
hospital-based 
paediatric 
gastrointestinal 
clinics.  
122 IBD adolescents mean 
age 15.7 (SD = 1.3) years, 
48.4% female 
 
UC: 26 
CD: 96  
Anxiety: not measured 
 
Depression: CDI ± cut-off 
N/A 
 
Disease activity: The 
Lichtiger Colitis Activity 
Index (LCAI), PCDAI, 
blood tests 
Depression: proportion above cut-off 
               CD 21.2 % 
               UC 16.7% (p=n.s.) 
 
 
Selinger et al. 
2013 (61) 
 
Australia 
 
Quality: 4/12 
cross-sectional; 
recruited from 
tertiary care 
hospital outpatient 
clinics and local 
office based 
gastroenterologists 
192 IBD patients, age N/A, 
53% female  
 
CD: 106 
UC: 124 
Anxiety: HADS ± cut-off 
>7  
 
Depression: not measured 
 
Disease activity: 
unspecified 
Anxiety: 
               CD M=7.2 
               UC M=6.6 (p=0.3) 
Sulz et al. 2013 
(62) 
 
Switzerland  
 
Quality: 6/12 
nationwide 
multicentre 
prospective 
observational 
population-based; 
must have 
been diagnosed at 
least 4 months 
before inclusion or 
had at least one 
recurrence 
1187 participants, median 
age 42.6±13.9, 53% females  
 
CD: 699 
UC: 488 
Anxiety: not measured 
 
Depression: HADS ± cut 
off >/= 8 
 
Disease activity: CDAI 
and TWI, blood 
 
Depression: proportion above cut-off 
                CD 17% 
                UC 18% (p=n.s.) 
 
Timmer et al. 
2007 (63) 
 
Germany  
 
Quality: 5/12 
Cross-sectional; 
consecutive males 
with IBD 
presenting to the 
departments of 
internal medicine 
and surgery, and 
randomly selected 
IURPWKHPHPEHUV¶
list of the national 
patient organization 
280 IBD males (4 groups A 
clinical population, B 
patient organisation) 
median age 38 years 
 
CD: 170 (61 in group A, 
109 in group B) 
UC: 110 (33 in group A, 77 
in group B) 
Anxiety: HADS > 10 
 
Depression: HADS > 10 
 
Disease activity: CDAI, 
CAI 
Anxiety: proportion above cut-off 
             CDA 33% 
             UCA 36% 
             CDB 17% 
             UCB 20% (p= N/A) 
 
Depression: proportion above cut-off 
             CDA 25% 
             UCA 18% 
             CDB 9% 
             UCB 9% (p= N/A) 
Timmer at al. 
2008 (64) 
 
Germany  
 
Quality: 4/12 
cross-sectional; 
females with IBD 
presenting to the 
university 
departments of 
internal medicine 
and surgery, and a 
random sample 
from the national 
patients 
organization  
336 IBD participants (4 
groups A clinical 
population, B patient 
organisation), median age 
38 years 
 
UC: 117 
 
CD: 219 
 
Anxiety: HADS > 10 
 
Depression: HADS > 10 
 
Disease activity: CDAI, 
CAI 
Anxiety: proportion above cut-off 
             CDA 37% 
             UCA 30% 
             CDB 30% 
             UCB 22% (p= N/A) 
 
Depression: proportion above cut-off 
             CDA 21% 
             UCA 35% 
             CDB 10% 
             UCB 10% (p= N/A) 
Van der Valk et 
al. 2014 (65) 
 
the Netherlands 
 
Quality: 8/12 
prospective 
cohort; web-based 
survey circulated to 
IBD outpatients at 
university hospitals 
and general 
hospitals   
2282 IBD participants 
 
UC: 909, mean age=46.1 
(SD 11.4), 55% female, 
83% in remission 
 
CD: 1,373, mean age=44.1 
(SD 11.8), 66% female, 
85% in remission 
Anxiety: not measured 
 
Depression: No scale name 
provided.  
 
Disease activity: patient 
self-reported 
 
Depression: proportion above cut-off 
              UC 9.9% 
               CD 10.3%; p= N/A 
Van Langenberg 
& Gibson 2014 
(26) 
 
Australia 
 
Quality: 5/12 
cross-sectional and 
longitudinal; 
recruited  
consecutively from  
hospital IBD clinic, 
invited in person at 
a clinic visit or 
through phone; age- 
and sex-matched 
cohort of healthy 
subjects was 
consecutively 
recruited through 
local advertisement 
 
294 IBD participants 
 
UC:113, mean age=50 
years (range 18±72), 55% 
female 
 
CD:181, mean age= 41 
years (range 18-68), 54% 
female  
 
 
Anxiety: HADS cut-off >7 
 
Depression: HADS cut-off 
>7 
 
Disease activity: HBI and 
SCCAI 
Anxiety:  
              UC  median=7 
              CD  median=8; p= N/A 
 
Depression:  
              UC median=7 
              CD median=8; p= N/A 
 
 
Vidal et al. 2008 
(46) 
 
Spain 
 
Quality: 6/12 
cross-sectional; 
recruited 
consecutively from 
those attending 
IBD outpatient 
hospital clinic 
147 IBD participants, mean 
age=37.2 years ( range: 18-
75), 51.7% female, 111 in 
remission 
 
UC:71 
CD:76 
 
Anxiety: HADS ± Cut-off 
score >8 
 
Depression: HADS ± Cut-
off score >8 
 
Disease activity:  CDAI, 
TWI 
Anxiety:  
            UC M=6.6 (SD 3.3) 
            CD M=7.6 (SD 3.7); p=n.s. 
 
Depression:  
             UC M=3.3 (SD 3.6) 
             CD M=4.2 (SD 3.4); p=n.s. 
 
Zhang et al. 2013 
(47) 
 
USA 
 
Quality: 6/12 
cross-sectional; 
recruited from  
university IBD 
program during 
regularly scheduled 
outpatient clinic 
appointments 
105 IBD participants, mean 
age=33 years (SD 12.9), 
45.5% female, 60 in 
remission 
UC: 50 
CD: 55 
Anxiety: not measured 
 
Depression: BDI II cut-off 
>/=14, BDI for Primary 
Care (BDI-PC) cut-off 
score >/=4 
 
Disease activity: CDAI, 
6HR¶V$FWLYLW\,QGH[6$, 
 
Depression: BDI II; BDI-PC 
      UC median=8.5 (SD 9.13); median=1.5 (SD 3.11) 
      CD median=8 (SD 7.38); median=2 (SD 2.67); 
p=n.s. 
           
Depression: proportion above cut-off 
                UC 20% 
                CD  29%    
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Table 5. Summary characteristics of the studies addressing controversy 4: Are rates of anxiety/depression in IBD similar or different to that reported in other groups of 
medically ill patients? (special populations indicated in grey) 
 
Authors, year 
and country 
Study information 
Design; setting; 
recruitment 
Participant characteristics 
(sample size, IBD type, 
age, sex) 
Measures 
anxiety, depression, 
disease activity  
Results  
Addolorato et al. 
2008 (27) 
 
Italy 
 
Quality: 7/14 
cross-sectional; 
consecutively 
recruited IBD 
outpatients from 
internal medicine 
outpatient setting 
1641 participants with GI 
disorders: mean age 43.9 
(SD=15.9), 57.8% female 
 
IBD: 135; 53 active UC, 41 
active CD, 21 inactive UC, 
20 inactive CD 
 
GI nonIBD: helicobacter 
pylori (Hp) (n=559), small 
intestinal bacterial 
overgrowth (SIBO) 
(n=554), sugar 
malabsorption (n=394), 
rrritable bowel syndrome 
(IBS) (n=309), coeliac 
disease (n=168), chronic 
hepatitis (n=122), gastro-
esophageal reflux disease 
(GERD) (n = 107), chronic 
gastritis without Hp 
infection (n=60), food 
allergy (n=25) 
 
Anxiety: STAI  
Cut-off score =40 
 
Depression: Zung Self-
Rating Depression 
Scale (Zung SDS)  
Cut-off score  >49 
 
Disease activity: 
CDAI, Truelove-Witts 
Index (TWI) 
 
 
Anxiety: proportion above cut-off 
              CD inactive (state) 55% 
              CD inactive (trait) 35% 
CD  inactive had lowest proportions compared to other 
13 conditions (p=N/A) 
              UC active  (state)  92.4% 
              Food allergies (state) 93% 
UC active had second highest proportion compared to 
other 13 conditions 
 
Depression: proportion above cut-off 
             UC inactive 0% 
             CD active 21.9%              
             IBS 51.7% 
UC inactive had lowest proportion of depression 
compared to other 13 conditions (p=N/A) 
Berrill et al. 2013 
(15)  
 
UK   
 
Quality: 8/14 
cross sectional; 
IBD and IBS adult 
outpatients 
attending 
gastroenterology 
hospital-based 
clinics; healthy 
controls from local 
advertising 
IBD: 150 (36%  CD) mean 
age 45.7 (11.3), 63% female   
 
IBS: 40, mean age  37.9 
(11.7) 67% female 
 
Healthy: 41, mean age 43.8 
(13.4), 61% female 
Age range for whole sample 
18 to 65 
Anxiety: HADS-A 
 
Depression: HADS-D 
 
Disease activity: fecal 
calprotectin 
Anxiety: IBD median=9, range 1-20 
               IBS controls median =11, range 0-20; (p=N/A) 
                        
             
Depression: IBD median= 5, range 0-16 
                    IBS median=5, range 0-16; (p=N/A) 
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Bol et al. 2010 
(67) 
 
the Netherlands 
 
Quality: 8/14 
cross-sectional; 
IBD patients 
recruited from 
database at GI 
clinic in medical 
center, age and sex-
matched; multiple 
sclerosis (MS) 
patients consecutive 
recruited from 
those referred to 
MS clinic in 
medical centre;  
IBD patients age 
and sex-matched to 
MS patients 
IBD: 76 UC, mean 
age=45.3 years (SD 8.8) 
68% female  
 
MS: 88, mean age=43.6 
years (SD 9.0), 70% female  
Anxiety:  not measured 
 
Depression: HADS-D 
 
Disease activity: CAI  
 
 
 
Depression:  UC mean=4.0 (SD 3.6) 
                     MS mean=5.6 (SD 4.0); p<0.01 
 
Brandi et al. 
2009 (68) 
 
Brazil 
 
Quality: 7/14 
 
cross-sectional; 
consecutive adult 
outpatients 
recruited from IBD 
centre at university 
hospital; 
consecutive adult 
GERD patients 
recruited from GI 
clinic at university 
hospital 
IBD: 110 CD, mean 
age=38.2 years (SD 10.8), 
50% female 
 
GERD: 110, mean 
age=39.9 years (SD 13.9) 
53% female 
 
Anxiety: HADS-A 
 
Depression: HADS-D; 
BDI 
Cut-off score HADS> 
8 
Cut-off score BDI >21 
 
Disease activity: CDAI 
Anxiety: proportion above cut-off 
               CD 33.6% 
               GERD 22.7%; p=n.s. 
 
Depression: BDI 
               CD mean=14, range 8-45 
               GERD mean = 13, range 4-49, p=n.s. 
 
Depression: proportion above cut-off 
               CD 25.4% 
               GERD 8.2%; p=0.003 
Bullen et al. 2012 
(69) 
 
Australia 
 
Quality: 5/14 
cohort study; 
recruited 
consecutive 
colorectal surgical 
patients with IBD 
or colon cancer 
prior to surgery 
IBD: 29, mean age=60.62 
years (SD 15.38), 59% 
female)  
 
Colon Cancer: 38, mean 
age=59.32 years (SD 
14.75), 50% female 
Anxiety: HADS-A 
 
Depression: HADS-D 
 
Disease activity: not 
specified 
Anxiety: IBD mean=5.93 (SD 3.38) 
               CC mean=7.22 (SD 4.74) 
(p=0.222) 
Depression: IBD mean=3.52 (SD 3.66) 
                    CC mean=4.43 (SD 4.65)  
(p=0.402) 
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Calsbeek et al. 
2006 (17) 
 
the Netherlands 
 
Quality: 5/14 
cross-sectional 
study; adolescents 
and young adults; 
recruited via 
medical specialists 
in academic and 
specialized 
hospitals; diagnosis 
at least 6 months. 
Controls with 
chronic liver 
diseases, congenital 
disorders, food 
allergy and coeliac 
disease.  
 
IBD: 305,  mean age=20 
years (SD 3.7),  54.8% 
females 
 
CLD: 94 with chronic liver 
diseases, mean age=19.4  
years (SD 4), 56.4% female 
 
ConD: 137 with congenital 
disorders, mean age= 18.1 
years (SD 3.8), 46.7% 
female 
 
FA: 98 with food allergy,  
mean age =18.5 years (SD 
3.8), 69.4% female  
 
CelD: 124 with celiac 
disease, mean age=17.5 
years (SD 3.7), 64.5% 
female 
Anxiety: HADS-A 
 
Depression: HADS-D 
 
Disease activity: not 
measured 
Anxiety: IBD mean=5.0 (SD 3.8) 
               CLD mean=6.2 (SD 4.4) 
               ConD mean=4.5 (SD 3.9) 
               FA mean=5.1 (SD 3.9) 
              CelD mean=3.7 (SD 3.2) (<0.001) 
 
Depression: IBD mean=2.8 (SD 2.9) 
                    CLD mean=3.6 (SD 3.5) 
                    ConD mean=2.4 (SD 2.7) 
                    FA mean= 2.6 (SD 2.5) 
                    CelD mean=2 (SD 2.2) (p=0.026) 
 
IBD participants had second highest anxiety and 
depression scores after chronic liver diseases. 
 
 
Castaneda et al. 
2013 (70) 
 
Finland 
 
Quality: 5/14 
cross-sectional; 
recruited 
consecutive 
adolescents with 
BD or juvenile 
idiopathic arthritis 
(JIA) from a 
FKLOGUHQ¶VKRVSLWDO 
 
 
IBD: 34; 17 CD, 16 UC, IC 
1, mean age =16.3 years 
(SD 1.7), 44% female 
 
JIA: 23, mean age=15.5 
years (SD 1.2), 61% female 
Anxiety: not measured 
 
Depression: BDI 
 
Disease activity: 
Physician Global 
Assessment, 
inflammatory markers 
(ESR, CRP, 
calprotectin) 
 
Depression: IBD mean=7.9 (SD 7.6) 
                    JIA mean=4.0 (SD 4.0); p=0.029 
 
)LOLSRYLüHWDO
2007 (71) 
 
Serbia 
 
Quality: 7/14 
cross-sectional; 
first episode IBD 
and newly 
diagnosed colon 
cancer (ColCa) 
recruited from 
hospital  
IBD: 32, 11 CD, 21 UC, 
mean age=49.2 (SD 16.58) 
59% female 
 
ColCa: 40, mean age=63.5 
(SD 9.14) 25% female 
$Q[LHW\+DPLOWRQ¶V
Anxiety Rating 
Inventory (HARI) 
 
Depression: 
+DPLOWRQ¶V'HSUHVVLRQ
Rating Inventory 
Anxiety: IBD mean=16.22 (SD 7.42) 
               ColCa mean=9.73 (SD 6.03); p<0.01 
 
Depression: IBD: mean=18.56 (SD 8.77) 
                    ColCa mean=10.83 (SD 5.26); p<0.001  
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(HDRI) 
 
Disease activity: 
CDAI, Ulcerative 
Disease Scoring 
System (UDSS) 
Jayanath et al. 
2014 (72) 
 
Malaysia. 
 
Quality: 5/14 
cross-sectional; 
children with a 
variety of GI issues 
recruited 
consecutively from 
a medical centre  
100 children, 49% aged 7±
12 years, 51% aged 13-17 
years old, 56% female  
 
IBD: 26 
FAP: 22 (functional 
abdominal pain) 
Biliary atresia: 17 
Other GI illnesses: 35  
 
 
Anxiety: not measured 
 
Depression: CDI cut-
off >55 (high score), 45-
55 (moderate) 
 
Disease activity: not 
specified 
Depression: proportion scoring moderate; high 
        IBD: 46.2%; 23.1%  
        FAP: 27.3%, 50.0% 
        Biliary atresia: 41.2%, 23.5% 
        Other GI: 51.4%, 17.1%  
Kovács & 
Kovács 2007 
(73) 
 
Hungary  
 
Quality: 7/14 
cross-sectional; 
recruited IBS 
patients presenting 
to GI unit; recruited  
age and sex-
matched IBD 
patient 
IBD: 43, mean age=38.4 
years (SD 12.9), 63% 
female 
 
IBS: 46, mean age=39.8  
years (SD 13.9), 70% 
female  
 
Anxiety: STAI 
 
Depression: BDI 
 
Disease activity: not 
reported 
Anxiety: IBD (state) mean =46.88 (SD 11.31) 
               IBS (state) mean=48.58 (SD 10.83); p=n.s. 
               IBD (trait) mean=46.80 (SD 11.75) 
               IBS (trait) mean=50.19 (SD 8.27); p=n.s. 
 
Depression:  IBD mean=11.62 (SD 9.72) 
                     IBS mean=15.84 (SD 7.88); p<0.05 
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Lerebours et al. 
2007 (21) 
 
France 
 
Quality: 11/14 
population-based 
case-control; 
recruited newly 
diagnosed IBD 
patients (< 6 
months) and self-
limited colitis 
(ASLC) patients 
identified from a 
registry of patients 
presenting with 
new GI symptoms 
IBD: 167 CD mean age= 
32.3 years (SD 13.1), 62% 
female; 74 UC mean 
age=36.1 years (SD 15.1), 
50% female 
 
ASLC: 69 mean age=40.6 
years (SD 17.2), 36 female 
 
 
Anxiety: Bates Anxiety 
Scale 
 
Depression: BDI-short 
Cut-off score>4 
 
Disease activity: 
unreported 
Anxiety: UC mean=40.31 (SD 21.65) 
               CD mean=52.2 (SD 25.2), 
               ASLC mean=46.99 (SD 22.93) 
               UC<ASLC p<0.002; CD=ASLC p=n.s. 
 
Depression: UC mean=6.13 (SD 4.93) 
                    CD mean=7.41 (SD 5.87) 
                    ASLC mean=5.01 (SD 3.96) 
           UC>ASLC p<0.002; CD >ASLC p<0.03 
 
Depression: proportion above cut-off 
                    UC 57% 
                    CD 61%  
                    ASLC 45%       
Miehsler et al. 
2008 (74) 
 
Austria 
 
Quality: 7/14 
cross-sectional; 
consecutive 
outpatients with 
IBD and 
rheumatoid arthritis 
(RA) recruited from 
clinic at a 
university hospital 
IBD: 302 mean age=37.3 
years (SD 11.8), 56% 
female 
 
RA: 109  mean age=53.3 
years (SD 12.6), 78% 
female 
Anxiety: HADS-A 
 
Depression: HADS-D 
Cut-off score >/=8; 
>/==11 
 
Disease activity: 
CDAI, CAI 
Anxiety: proportion above cut-off 8; above cut-off 11 
               IBD 37%;                 IBD 18% 
               RA 25%; p=0.02      RA 14%;p=n.s. 
 
Depression: IBD 18%;            IBD 7% 
                    RA 29%; p=0.01 RA15%; p=0.02 
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Mikocka-Walus 
et al. 2008 (75) 
 
Australia  
 
Quality: 5/14 
cross-sectional ; 
recruited 
consecutive 
outpatients with 
IBD, hepatitis C 
(HepC), and IBS 
from a 
gastroenterology 
outpatient clinic 
 
 
IBD: 64, mean age=51 
years (SD 15), 61% female 
 
HepC: 41, mean age=45 
years (SD 10), 49% female 
 
IBS: 34 mean age=54 years 
(SD 13), 77% female 
 
 
Anxiety: HADS-A cut-
off >/=8; SCL90-A 
 
Depression: HADS-D 
cut-off >/=8; 
SCL90-R-D  
 
Disease activity : 
CDAI, SCCAI 
Anxiety: HADS-A 
               IBD: mean=6.57 (SD 3.44) 
               HepC mean=6.97 (SD 4.83) 
               IBS mean=7.97 (SD 2.92); p=n.s. 
               SL90-A 
               IBD mean=51.79 (SD 9.74) 
               HepC mean=57.63 (SD 13.61)  
               IBS mean=56.82 (SD 8.77) 
               HepC > IBD, p=0.013 
 
Anxiety: proportion above cut-off 
                IBD N/A% 
                HepC N/A% 
                IBS  N/A%; p=n.s. 
 
Depression: HADS-D 
                    IBD mean=4.07 (SD 2.86) 
                    HepC mean=5.36 (SD 4.96) 
                    IBS mean=4.29 (SD 3.70); p=n.s. 
                    SCL90-D 
                    IBD mean=58.04 (SD 9.94), 
                    HepC mean=62.26 (SD 12.50) 
                    IBS mean=59.99 (SD 10.16); p=n.s. 
 
Depression: proportion above cut-off 
                     IBD   11% 
                     HepC 34% 
                     IBS    15% 
              HepC>IBD/IBS p=0.009 
Naliboff et al. 
2012 (76) 
 
USA 
 
Quality: 4/14 
cross-sectional; 
recruited IBD and 
IBS patients seen in 
a university 
medical centre 
IBD: 126, mean age=40.5 
years (SD 13.3), 53% 
female 
 
IBS: 564, mean age=46.7 
years (SD 13.7), 69% 
female  
Anxiety: SCL90R-A 
 
Depression: SCL90-D 
 
Disease activity: 
unreported 
Anxiety: IBD mean=53.08 (SD 12.61) 
               IBS mean=54.10 (SD 11.58); p=n.s. 
 
Depression: IBD mean=58.78 (SD 11.28) 
                    IBS mean=58.30 (SD 10.36); p=n.s. 
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Piche et al. 2010 
(24) 
 
France 
 
Quality: 7/14 
cross-sectional; 
CD and IBS 
participants 
recruited from 5 
university hospitals 
 
IBD: 92 CD in remission, 
mean age=35.9 years (SD 
12.3), 59% female 
 
IBS: 40, mean age=40.9 
years (SD 9.5); 70% female 
Anxiety: HADS-A 
 
Depression: BDI-S  
 
Disease activity: 
CDAI, Haemoglobin, 
CRP, ESR, platelet 
count, albumin 
Anxiety:  
     CD with IBS-type symptoms      mean=8.7 (SD 3.9)  
     CD without IBS-type symptoms mean=8.5 (SD 3.4) 
     IBS                                               mean=9.7 (SD 4.5) 
     p=n.s. 
 
Depression:   
    CD with IBS-type symptoms      mean=6.4 (SD 5.6) 
    CD without IBS-type symptoms mean=4.2 (SD 3.9) 
    IBS                                              mean=5.9 (SD 5.4)  
    p=n.s. 
Seres et al. 2008 
(77) 
 
Hungary 
 
Quality: 5/14 
cross-sectional; 
recruited IBD and 
IBS patients 
presenting at three 
ambulatory tertiary 
care 
gastroenterology 
departments 
IBD: 66 UC, mean age 
=38.89 years (SD 13.30), 
70% female  
 
IBS: 88, mean age =41.59  
years (SD 13.71) , 81% 
female 
Anxiety: SCL90R-A 
 
Depression: SCL90R-
D 
 
Disease activity: 
unreported 
Anxiety: UC mean (raw score)= 0.88 (SD  0.75) 
               IBS mean (raw score)=1.26 (SD  0.90);p<0.01 
 
Depression:  
               UC mean (raw score)= 1.13 (SD 0.87) 
               IBS mean (raw score)=1.45 (SD 0.98); p<0.05 
7NDOþLüHWDO
2010 (78) 
 
Croatia  
 
Quality: 6/14 
cross-sectional; 
recruited 
consecutive IBD 
and IBS patients 
from university 
gastroenterology 
clinic 
IBD: 43, mean age=42.90 
years (SD 15.44), 49% 
female 
 
IBS: 56,  mean age=48.64 
years (SD 13.04), 64% 
female 
 
 
Anxiety: STAI 
 
Depression: BDI cut-
off >/=13 
 
Disease activity: 
CDAI, CAI 
Anxiety: IBD mean=34.51 (SD 12.10) 
               IBS mean=40.98 (SD 11.68); p<0.01 
 
Depression:  IBD mean=12.44 (SD 7.48) 
                     IBS mean=13.0 (SD 7.37); p=n.s. 
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Table 6. Summary characteristics of the studies addressing controversy 5: Do anxiety and depression precede and/or follow onset of IBD? (special populations indicated in 
grey) 
Authors, year 
and country 
Study 
information: 
Design; setting; 
recruitment  
Participant 
characteristics (sample 
size, IBD type, age, sex) 
Measures 
Anxiety, depression, 
disease activity 
Results  
Loftus et al. 2011 
(22) 
 
USA 
 
Quality: 12/14 
retrospective 
cohort; 
observations from 
minimum of 6 
months to a 6.5 
years; youth; IBD 
and nonIBD age 
and sex-matched 
cases taken from 
national database 
of health service 
claims data for 
approximately 
100 third-party 
payers, including 
employers and 
health plans;  
IBD: 2,144 CD cases  
 
Controls: 10,720 
nonIBD cases  
Both groups: mean age at 
index date 11.8 years,  
(SD 0.4) ,46.1% female 
 
 
Anxiety: ICD 9 CM codes 
293.84, 300.0x, 313.0x 
(includes anxiety states and 
disorder) 
Depression: ICD 9 CM 
codes 296.2x, 296.3x, 
298.0x, 300.4x, 309.1x, 
311.xx (includes major 
depressive disorder, 
depressive type psychosis, 
dysthymia) 
 
Disease activity: based on 
treatment history 
 
Anxiety:  
         CD incident rate=1.81 cases per 100 patient years 
         Controls incident rate= 0.57 cases; p<0.0001  
   
x Having CD increased the risk of developing an 
anxiety disorder (adjusted HR=2.28, 95% 
CI=1.65-3.17) p<0.0001 
x teenaged girls with CD had an increased risk 
of developing an anxiety disorder (HR = 2.45; 
95% CI = 1.41±4.25) 
x teenaged boys with CD aged 13-17  had an 
increased risk of developing an anxiety 
disorders (HR = 3.01; 95% CI = 1.73± 5.24). 
  
  CD persistent anxiety rate=0.53/ 100 patient years 
  Controls persistent anxiety rate=0.09/100 patient  
                years; p<0.0001 
 
x Having CD increased the risk of developing a 
persistent anxiety disorder (adjusted HR = 4.35; 
95 % CI = 2.22 ± 8.50). 
 
Depression:  
          CD incident rate=2.69 cases per 100 patient years 
          Controls incident rate=1.22 cases; p<0.0001 
 
x Having CD increased the risk of developing 
depression (adjusted HR=1.74, 95% CI=1.35-
2.25) p<0.0001 
x CD boys aged 12 years or younger had an 
increased risk of developing depression (HR = 
2.55; 95% CI = 1.15±5.67) 
x teenaged boys with CD aged 13-17 years 
had an increased risk of developing depression 
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(HR = 1.99; 95% CI = 1.32± 3.02)  
     
  CD persistent depression rate=0.87/ 100 patient years 
  Controls persistent depression rate=0.26/100 patient  
                years; p<0.0001  
 
x Having CD increased the risk of developing 
persistent depression (adjusted HR=2.75, 95% 
CI=1.73-4.38) 
Walker et al. 2008 
(9) 
 
Canada 
 
Quality: 11/14 
population-based 
cohort; 24 
months 
observation; 
recruited from 
province-wide 
university IBD 
research registry; 
control cases 
obtained from 
national health 
survey and age, 
gender and 
region-matched  
IBD: 351 participants, 
mean age=43 years (SD 
14.06), 60% female, 95% 
Caucasian, 48% CD, 
46% UC/ulcerative 
proctitis, 6% 
indeterminate colitis.  
 
Controls: 779 cases, 
mean age=40 years (SD 
14.51), 59.1% female 
 
 
Anxiety: 12 month and 
lifetime prevalence of 
anxiety disorders assessed 
by Comprehensive 
International Diagnostic 
Interview (CIDI);  
 
Depression: 12 month and 
lifetime prevalence of mood 
disorders assessed by CIDI 
 
Disease activity: MIBDI 
 
 
Anxiety disorder: 
1st onset 10 years or more before IBD onset: 70% 
1st onset 2-9 years before IBD onset:              9% 
1st onset and IBD onset < 2 years apart:         13% 
1st onset 2 or more years after IBD onset:      8% 
 
Mood disorder:  
1st onset 10 years or more before IBD onset: 31% 
1st onset 2-9 years before IBD onset:              23% 
1st onset and IBD onset < 2 years apart:          23% 
1st onset 2 or more years after IBD onset:       23% 
  
Mean age of IBD symptom onset with lifetime anxiety 
or mood disorder:   29.1 years 
Mean age of IBD symptom onset without anxiety or 
mood disorder:        33.1 years.; p=0.012  
 
Direct comparisons with matched controls (with data 
available for three anxiety disorders) found lifetime 
prevalence (IBD vs controls) as follows: social anxiety 
disorder lower in IBD (6% vs 11%, OR 0.52, 95% CI 
0.32±0.85), panic disorder not significantly different 
(8.0% vs 4.7%, OR 1.59, 95% CI 0.96±2.63), 
agoraphobia without panic not significantly different 
(1.1% vs 0.6%, OR 1.44, 95% CI 0.37±5.55), and major 
depression higher (27.2% vs 12.3%, OR 2.20, 95% CI 
1.64±2.95). 
 
Table 7: Summary of evidence for controversies in relation to co-occurrence of anxiety and 
depression with IBD 
Controversy Answer to controversy Confidence level* 
1 IBD versus healthy/general 
population controls 
Rates of anxiety and depression 
higher in IBD participants 
compared to healthy controls 
 
MODERATE 
 
2 IBD active versus IBD 
inactive 
Rates of anxiety and depression 
higher in those with active 
compared to inactive IBD 
MODERATE 
 
3 CD versus UC Rates of anxiety and depression 
modestly higher in those with CD 
compared to UC 
MODERATE 
 
 
4 IBD versus medically ill 
controls 
Rates of anxiety and depression 
lower in IBD participants 
compared to those with other, 
primarily gastrointestinal, chronic 
illnesses 
MODERATE 
 
 
 
5 Preceding or following IBD 
onset 
No prospective studies on anxiety 
or depression preceding IBD.  
 
Adults with IBD more likely to 
develop anxiety prior to IBD 
onset; more likely to develop 
depression prior to IBD onset, but 
substantial proportion develop 
depression after onset. In children, 
higher risk of developing either 
anxiety or depression after IBD 
onset compared to controls. 
HIGH 
* based on the quality appraisal process 
